BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<u>http://bmjopen.bmj.com</u>).

If you have any questions on BMJ Open's open peer review process please email <u>editorial.bmjopen@bmj.com</u>

BMJ Open

Secondhand tobacco smoke exposure and pulmonary function among non-smoking employees of bar and restaurants in Santiago, Chile

Journal:	BMJ Open
Manuscript ID	bmjopen-2017-017811
Article Type:	Research
Date Submitted by the Author:	19-May-2017
Complete List of Authors:	Parro, Javiera; Universidad de Los Andes, Facultad de Enfermería Aceituno, Paulina; Universidad de Chile, Facultad de Medicina, Escuela de Salud Pública Droppelmann, Andrea; Instituto de Salud Pública, Laboratorio de Salud Ocupacional Mesías, Sthepanie; Universidad de Chile, Facultad de Medicina, Escuela de Salud Pública muñoz, claudio; Universidad de La Frontera, Facultad de Medicina Marchetti, Nella; Universidad de Chile, Facultad de Medicina, Escuela de Salud Pública Iglesias, Verónica; Universidad de Chile, Facultad de Medicina, Escuela de Salud Pública
Primary Subject Heading :	Occupational and environmental medicine
Secondary Subject Heading:	Smoking and tobacco
Keywords:	Secondhand smoke exposure, chronic exposure, pulmonary function, urine cotinine, workers
	SCHOLARONE [™] Manuscripts

BMJ Open

Secondhand tobacco smokeexposure and pulmonary function among non-smoking employees of bar and restaurantsin Santiago, Chile Javiera Parro. Escuela de Enfermería, Universidad de Los Andes. Santiago, Chile. Paulina Aceituno. Escuela de Salud Pública, Facultad de Medicina, Universidad de Chile. Santiago, Chile. Andrea Droppelmann. Laboratorio de Salud Ocupacional, Instituto de Salud Pública. Santiago, Chile. Sthepanie Mesías. Escuela de Salud Pública, Facultad de Medicina, Universidad de Chile. Santiago, Chile. Claudio Muñoz. Facultad de Medicina, Universidad de La Frontera. Temuco, Chile. Nella Marchetti. Escuela de Salud Pública, Facultad de Medicina, Universidad de Chile. Santiago, Chile. Verónica Iglesias, Escuela de Salud Pública, Facultad de Medicina, Universidad de Chile. Santiago, Chile. Corresponding author: Verónica Iglesias Alamos. Postal address: Independencia 939, Independencia, Santiago Chile, 8380453. Email: viglesia@med.uchile.cl.

Telephone number: 56-229786397.

Word count: 2.595

Abstract

Introduction. The workplace remains a significant source of secondhand smoke (SHS) exposure. This pollutant is known to be associated with respiratory and cardiovascular problems, but its effects on specific pulmonary function parameters remain largely unexplored. The objectives of this study were to measure SHS exposure among non-smoking employees of bar and restaurantsin Santiago, Chile and to evaluate the effects of such exposure on pulmonary function.

Methods. Cross-sectional design. The study sample included non-smoking workers from 57 restaurants and bars in Santiago, Chile. The outcome variable was pulmonary function and the exposure variables were urine cotinine concentration, a biomarker for current SHS exposure, and years of SHS exposure in the workplace as proxy of chronic exposure. Personal and occupational variables were also recorded. Data analysis was performed using linear regression models adjusted by confounders.

Results. The median age of the workers was 35 years and the median employment duration at the analysed venues was 1 year. Workers in smoking facilities reported greater SHS exposure (36 hours per week) than workers in smoke-free locations (4 hours per week). Urine cotinine levels were inversely correlated with forced vital capacity (FVC), but the finding was not statistically significant (β =-0.0002; 95% CI: -0.007 to 0.006). Years of exposure to SHS showed to be significantly associated with FEF25 / 75 (β = -0.006; 95% CI: -0.010 to -0.0004).

Conclusion. These findings suggest that cumulative exposure to SHS at work may contribute to deterioration of pulmonary function in non-smoking employees.

BMJ Open

Keywords: Secondhand smoke exposure, chronic exposure, pulmonary function, urine cotinine, workers.

Strengths and limitations of this study

- The effects of occupational SHS exposure on specific pulmonary function parameters has been scarcely explored.

- This study is the first in Chile to evaluate occupational SHS exposure and its association with specific pulmonary function parameters.

- The use of the variable "number of years exposed to SHS at workplace" was appropriate to studied chronic SHS exposure.

- Our sample included mainly young workers being reasonable to infer that the sample not accumulated sufficient years of SHS exposure to register greater changes in pulmonary function.

- Daily fluctuations of the timing of the spirometry measurements may have affected the results, since these were performed at various times of day, according to the availability and shifts of the workers and establishments.

Introduction

Secondhand smoke (SHS) is the smoke that remains in the air after someone has consumed tobacco, including the smoke coming from the burning end of the cigarette and the smoke exhaled by the smoker ^{1, 2, 3, 4}. SHS is a common indoor pollutant in restaurants and bars

BMJ Open: first published as 10.1136/bmjopen-2017-017811 on 6 October 2017. Downloaded from http://bmjopen.bmj.com/ on April 19, 2024 by guest. Protected by copyright

that poses a serious health risk for non-smokers as it contains over 50 substances known to be carcinogenic in humans. There is no known safe exposure level 1,4 .

Because SHS contains the same toxic substances that a smoker inhales, SHS exposure can lead to the same health problems associated with active smoking ⁵, with risk levels increasing as a function of hours of exposure ^{6, 7, 8, 9, 10}. Common scenarios associated with chronic SHS exposure include living with a spouse or parent who smokes and working in a location where smoking is allowed ^{2, 4}. Previous studies have not been consistent in showing a decline in specific pulmonary function parameters in people affected by SHS exposure at work or at home (Table 1). This lack of evidence may be attributable to the methods use to measure SHS exposure, which range from self-report ^{11, 12, 13, 14} to measurement of exposure biomarkers ^{11, 12, 13, 14, 15}.

Author	Sample	Exposure assessment	Source of	Main results
(year)	size		exposure	
Kunzli et al. (2000)	3534	Questionnaire	Occupational	FEV ₁ (β= -0.1%; CI95% -1.3 to 1.1%) FVC (β= -0.7%; CI95% -0.4 to 1.8%) FEF 25/75 (β=-1.9%; CI95% -4.2 to 0.5%)
Janson et al. (2001)	7882	Questionnaire	Total exposure*	FEV ₁ (β= -63 ml; CI95% -111 to -15 ml)
Chen et al. ⁽²⁰⁰¹⁾	301	Questionnaire. Are you regularly exposed to tobacco smoke from other people? Three sources of exposure of SHS were given; workplace, home, and other places. On average, for how many hours a day are you exposed to other people's tobacco smoke?. Blood cotinine	Occupational	FEV ₁ (β= -254 ml; Cl95% -84 to -240 ml) FVC (β= -273 ml; Cl95% -60 to -480 ml)
Eisner (2002)	10581	Questionnaire. Does anyone who lives here smoke cigarettes in the home? At work, how many hours per day are you close enough of people who smoke so that you can smell the smoke? Exposure dif was ≥ 1 hr a day. Blood cotinine.	Total exposure*	FEV ₁ (β= -100 ml; CI95% -143 to -56 ml) FVC (β= -119 ml; CI95% -168 to -69 ml) FEV ₁ /CVF (β= -1,77%; CI 95% -2.18 to - 1.36%)
Fidan et al. ⁽²⁰⁰⁴⁾	207	Questionnaire	Occupational	FEV ₁ (β= -5.1%; p value=0.011) FVC (β= -3.4%; p value=0.080)
Alipour et al. (2005)	302	Questionnaire	Occupational Total exposure*	FEV ₁ (β = 2.45%; CI95% -5.17 to -0.28%) FEV ₁ (β = 2.90%; CI95% -5.59 to -0.23%) FVC (β = -3.16%; CI95% -5.67 to -0.64%) FEF 25/75 (β = -9.87%; p value=0.009)
Fahim et al. (2012)	55	Questionnaire	Occupational	FVC (β = -6%; p value=0.041) VEF ₁ /FVC (β = -4.2%; p value=0.001) FEF ₇₅ (β = -7.5%; p value=0.017)

One of the most common ways of measuring SHS exposure is measuring concentration of cotinine, the principle metabolite of nicotine. Cotinine can be measured in the blood or urine and shows high sensitivity and specificity for acute SHS exposure (over the past 3–4 days), although some authors have also used it to evaluate longer-term exposure ^{16, 17, 18}. Chronic exposure to SHS has been measured through questionnaire and by hair nicotine concentration ^{19, 20}.

In 2010, the time at which this study was performed, Chilean law prohibited tobacco smoking in public areas and workplaces. However, there were exceptions for "hospitality"

venues, such as casinos, bars, pubs, restaurants, and cafés. Bars, pubs, and restaurants with areas smaller than 100 m^2 could choose to allow smoking indoors or not, while facilities with an area larger than 100 m^2 were required to offer separate sections for smokers and nonsmokers. Therefore, "hospitality" workers were unprotected from SHS exposure, becoming the workplace, in many cases, the main source of SHS exposure $^{21, 22}$.

The objectives of this study were to measure SHS exposure among non-smoking workers in restaurants and bars in Santiago, Chile and to evaluate the effects of such exposure on pulmonary function.

Methods

This cross-sectional study was performed as part of a larger project, "Impact of involuntary exposure to tobacco smoke on respiratory health: study of pub and restaurant workers", carried out in Santiago, Chile between September 2010 and January 2011. This study was approved by the University of Chile School of Medicine's Ethics Committee.

Population and sample

The selection process for participating facilities has been previously described in detail ²³. In brief, the sampling framework included the 5 municipalities with the largest numbers of facilities, according to data provided by the National Institute of Statistics (Spanish acronym INE, for *Instituto Nacional de Estadísticas*). Study staff visited 690 locations and used a brief survey to record the venue's name, address, type of facility (bar/pub, restaurant, or other), smoking status (smoking allowed in all areas; designated smoking/non smoking areas; or smoke-free), and number of non-smoking workers. Of the 690 facilities, 207 met inclusion criteria (be a bar-pub or restaurant and have non-smoking workers). Of them, 108 were visited or contacted by telephone to invite the owner or manager to participate in the

study. In 63 establishments they agreed to participate (58%). For logistical reasons, only 59 of the facilities were included²³. Non-smoking workers in these facilities were then invited to participate in the study. Workers were excluded if they did not provide a urine sample (n=5) or had a contraindication for spirometry (n=1) ^{24, 25}. A total of 92 non-smoking workers participated in the study after providing written informed consent.

Outcome variables

Pulmonary function parameters: Certified personnel used an *Easy One Diagnostic*® to measure forced vital capacity (FVC) and forced expiratory volume in 1s (FEV₁), and then calculated the FEV₁ to FVC ratio (FEV₁/FVC) and forced expiratory flow as 25%–75% of FVC (FEF₂₅₋₇₅). Spirometry measurements were performed during working hours. In compliance with international norms on collecting and interpreting spirometry data, age, sex, weight, height, and race of each participant were also recorded ^{24, 25}. A maximum of 8 spirometry trials were performed. The criteria for including a participant's spirometry data in the analysis was achieving at least 3 acceptable and 2 reproducible trials, as described in the norms published by Spanish Society of Pneumology and Thoracic Surgery (Spanish acronym SEPAR, for *Sociedad Española de Neumología y Cirugía Torácica*) ^{24, 25}. The equipment was calibrated weekly.

Exposure variables

Urine cotinine concentration. Each worker was asked to provide urine sample the morning after the spirometry measurements. The sample was provided, retrieved, and frozen on the same day. Urine cotinine concentration was measured using ELISA at a sensitivity of 1 ng/ml. The cut-off value typically used in the literature to distinguish smokers from non-

smokers is 10 ng/ml²⁶. As a quality control, duplicate samples were obtained and analyzed. There was a strong correlation between the original and duplicate samples (Spearman's correlation=0.96; p-value=0.0005). Chronic exposure to SHS was measured as *the number of years exposed to SHS at workplace* (number of years worked at their 3 most recent job positions and whether it involved SHS exposure).

Covariables

The questionnaire included items about the participant's health history (asthma diagnosis, smoking habits); occupational history (job function at the facility, secondary employment at another facility, number of hours per day and days per week worked); occupational exposure (number of hours per day and days per week exposed to SHS); and the type of facility (smoking, mixed, or non-smoking).

Statistical analysis

Data analysis was performed using the program STATA 12. The quantitative variables were assessed for normality using the Shapiro-Wilk test. Descriptive statistics were calculated, including median and interquartile ranges (P_{25} – P_{75}) for quantitative variables and relative frequency for qualitative variables. Quantitative exposure variables and covariables, such as number of hours per week of SHS exposure or age were dichotomized using the median as cutoff. Kruskal Wallis test and Wilcoxon test were used to assess difference of pulmonary parameters and exposure variables between the categories of the covariables. Finally, the association between pulmonary function parameters and exposure to SHS was analyzed using multiple linear regression models adjusted by covariates

potentially associated with both, the outcome and the exposure considering a p-value of $< 0.10^{27}$, as well as variables commonly controlled for in the literature.

Results

A total of 17 participants (18.5%) were excluded due to spirometry results that failed to meet the criteria for acceptability and reproducibility. The final sample was 75 workers. Median age was 35 years (P_{25} – P_{75} : 19–68 years), and 61% of participants were male. On average, participants had worked at the studied venue for 12 months. Independent of the facility type, the sample was mainly composed of waiting staff, bartenders, and cashiers (58.7%), followed by owners or managers (28%), and finally cooks (13.3%). The number of hours worked per week was similar for workers in smoking, mixed, and non-smoking facilities. Workers in smoking facilities reported higher number of weekly hours and number of years exposed to SHS compared to workers in mixed and non-smoking facilities (Table 2).

	bar/pub		
	Smoking	Mixed	Non-smoking
N° employees (%)	27 (36.0)	31 (41.3)	17 (22.7)
Sociodemographic characteristics			
Age, Median $(P_{25}-P_{75})$	40.0 (32.0-47.0)	35.0 (24.0-47.0)	31.0 (23.0-42.0)
Sex, n (%)			
Male	17 (63.0)	19 (61.3)	10 (59.0)
Scholarship, n (%)			
≤8 years	3 (11.1)	2 (6.5)	-
9-12 years	11 (40.8)	19 (61.3)	11 (64.7)

Table 2. Characteristics	of the study sample.	. Santiago,	Chile 2010-2011.

BMJ Open: first published as 10.1136/bmjopen-2017-017811 on 6 October 2017. Downloaded from http://bmjopen.bmj.com/ on April 19, 2024 by guest. Protected by copyright

>12 years	13 (48.1)	10 (32.2)	6 (35.3)
Asthma, n (%)			
Yes	1 (3.7)	7 (22.6)	-
No	26 (96.3)	24 (77.4)	17 (100)
Occupational exposure			
Job function at the facility, n (%)			
Owners/managers	7 (25.9)	1 (3.2)	13 (76.5)
Wait staff/bartenders/cashiers	13 (48.2)	27 (87.1)	4 (23.5)
Cooks	7 (25.9)	3 (9.7)	-
Number of months of work in the local, Median $(P_{25}-P_{75})$	12.0 (1.0-192.0)	9.0 (1.0-468.0)	12.0 (2.0-60.0)
Number of weekly working hours, Median (P25-P75)	48.0 (40.0-54.0)	48.0 (40.0-60.0)	45.0 (40.0-48.0)
Number of hour per week exposed to SHS, Median (P_{25} - P_{75})	36.0 (21.0-56.0)	28.0 (6.0-48.0)	4.0 (2.0–7.0)
Number of years exposed to SHS workplace, Median (P_{25} - P_{75})	3.0 (0.9-7.1)	2.2 (0.8-6.9)	1.5 (0.0-5.0)

As shown in Table 3 we compared the results for pulmonary function and urine cotinine concentration based on covariables. Males had greater pulmonary function values than females, except for FEV₁/FVC ratio, where no differences were observed. In terms of the occupational exposure variables, employees working in the kitchen had lower values for FVC, FEV₁, and FEF_{25/75} than the group of wait staff, bartenders, cashiers, and managers. Regarding the number of hours per week of SHS exposure and pulmonary function, exposure greater than 26 hours per week was associated with a 0.02% decrease in FEV₁/FVC and a 230 ml decrease in FEF_{25/75} although these results were not statistically significant. Workers in smoking venues had FEF_{25/75} 400 ml lower and FEV₁/FVC ratios 0.03% lower than those of workers in non-smoking venues. In terms of urine cotinine concentration, owners and managers had the highest levels, followed by kitchen workers

Table 3. Urine cotinine concentration and pulmonary function at non-smoking workers. Santiago, 2010-2011.

and then finally the group	o of	wait staff, bart	enders, and ca	shiers (44.4 ng	g/ml, 25.0 ng/r	nl,
and 13.2 ng/ml, respective	ely).	Urine cotinine	e concentration	varied by nun	nber of hours p	ber
veek of SHS exposure a	s sel	f-reported by j	participants and	d by the smok	ting status of t	he
acility. Workers with over	er 26	hours per wee	ek of SHS exp	osure had urin	e cotinine valu	ies
4.5 ng/ml higher than th	ose v	who reported 2	6 or fewer hou	irs of exposure	ner week wh	ile
		-		-	-	
workers in smoking facili	ties s	show levels of	urine cotinine	1/./ ng/ml hig	ther than worke	ers
n non-smoking facilities.						
Fable 3. Urine cotinine con	icent	ration and puln	nonary function	n at non-smokir	ng workers.	
Santiago, 2010-2011.						
8 /						
Variables			Pulmonary fund	ction parameters		Urine cotin concentrati
Variables	n	FVC	Pulmonary fund FEV ₁	FEV ₁ /FVC	FEF 25%/75%	Urine cotin concentrati (ng/ml)
Variables	n	FVC ml (RIC)*			FEF 25%/75% (ml)	_ concentrati (ng/ml) Med (P ₂₅ -P
	n		FEV_1	FEV ₁ /FVC		_ concentrati (ng/ml) Med (P ₂₅ -P
	n 46		FEV_1	FEV ₁ /FVC		_ concentrati (ng/ml) Med (P ₂₅ -P
Variables Sex Male Female		ml (RIC)*	FEV ₁ ml (RIC)*	FEV ₁ /FVC (%)	(ml)	_ concentrati (ng/ml) Med (P ₂₅ -P 18.6 (6.2-39 13.6 (7.3-41
Sex Male	46	ml (RIC)* 4.82 (4.23-5.42)	FEV ₁ ml (RIC)* 3.94 (3.41-4.38)	FEV ₁ /FVC (%) 0.81 (0.76-0.84)	(ml) 3.95 (3.00-4.66)	_ concentrati (ng/ml) Med (P ₂₅ -P 18.6 (6.2-39 13.6 (7.3-41
Sex Male Female p value ±	46	ml (RIC)* 4.82 (4.23-5.42) 3.48 (3.16-3.90)	FEV ₁ ml (RIC)* 3.94 (3.41-4.38) 2.89 (2.65-3.34)	FEV ₁ /FVC (%) 0.81 (0.76-0.84) 0.81 (0.79-0.89)	(ml) 3.95 (3.00-4.66) 3.25 (2.56-3.83)	_ concentrati (ng/ml) Med (P ₂₅ -F 18.6 (6.2-39 13.6 (7.3-41
Sex Male Female p value ±	46	ml (RIC)* 4.82 (4.23-5.42) 3.48 (3.16-3.90)	FEV ₁ ml (RIC)* 3.94 (3.41-4.38) 2.89 (2.65-3.34)	FEV ₁ /FVC (%) 0.81 (0.76-0.84) 0.81 (0.79-0.89)	(ml) 3.95 (3.00-4.66) 3.25 (2.56-3.83)	_ concentrati (ng/ml) Med (P ₂₅ -F 18.6 (6.2-39 13.6 (7.3-41 0.944
Sex Male Female p value ± Age	46 29	ml (RIC)* 4.82 (4.23-5.42) 3.48 (3.16-3.90) 0.0001	FEV ₁ ml (RIC)* 3.94 (3.41-4.38) 2.89 (2.65-3.34) 0.0001	FEV ₁ /FVC (%) 0.81 (0.76-0.84) 0.81 (0.79-0.89) 0.116	(ml) 3.95 (3.00-4.66) 3.25 (2.56-3.83) 0.014	_ concentrati (ng/ml) Med (P ₂₅ -P 18.6 (6.2-39 13.6 (7.3-41 0.944
Sex Male Female p value ± Age ≤35 years *	46 29 38	ml (RIC)* 4.82 (4.23-5.42) 3.48 (3.16-3.90) 0.0001 4.79 (3.93-5.36)	FEV ₁ ml (RIC)* 3.94 (3.41-4.38) 2.89 (2.65-3.34) 0.0001 3.91 (3.37-4.38)	FEV ₁ /FVC (%) 0.81 (0.76-0.84) 0.81 (0.79-0.89) 0.116 0.83 (0.79-0.88)	(ml) 3.95 (3.00-4.66) 3.25 (2.56-3.83) 0.014 4.07 (3.27-4.59)	_ concentrati (ng/ml) Med (P ₂₅ -P 18.6 (6.2-39 13.6 (7.3-41 0.944
Sex Male Female p value ± Age ≤35 years * >36 year p value ±	46 29 38	ml (RIC)* 4.82 (4.23-5.42) 3.48 (3.16-3.90) 0.0001 4.79 (3.93-5.36) 3.78 (3.21-4.42)	FEV ₁ ml (RIC)* 3.94 (3.41-4.38) 2.89 (2.65-3.34) 0.0001 3.91 (3.37-4.38) 2.95 (2.61-3.62)	FEV ₁ /FVC (%) 0.81 (0.76-0.84) 0.81 (0.79-0.89) 0.116 0.83 (0.79-0.88) 0.80 (0.78-0.83)	(ml) 3.95 (3.00-4.66) 3.25 (2.56-3.83) 0.014 4.07 (3.27-4.59) 3.12 (2.53-3.95)	_ concentrati (ng/ml) Med (P ₂₅ -P 18.6 (6.2-39 13.6 (7.3-41 0.944
Sex Male Female p value ± Age ≤35 years * >36 year p value ±	46 29 38	ml (RIC)* 4.82 (4.23-5.42) 3.48 (3.16-3.90) 0.0001 4.79 (3.93-5.36) 3.78 (3.21-4.42)	FEV ₁ ml (RIC)* 3.94 (3.41-4.38) 2.89 (2.65-3.34) 0.0001 3.91 (3.37-4.38) 2.95 (2.61-3.62)	FEV ₁ /FVC (%) 0.81 (0.76-0.84) 0.81 (0.79-0.89) 0.116 0.83 (0.79-0.88) 0.80 (0.78-0.83)	(ml) 3.95 (3.00-4.66) 3.25 (2.56-3.83) 0.014 4.07 (3.27-4.59) 3.12 (2.53-3.95)	_ concentrati (ng/ml) Med (P ₂₅ -P 18.6 (6.2-39 13.6 (7.3-41 0.944 21.4 (5.1-40 15.2 (9.7-38 0.787 44.4 (29.3-46
Sex Male Female p value ± Age ≤35 years * >36 year p value ± Job function at the facility	46 29 38 37	ml (RIC)* 4.82 (4.23-5.42) 3.48 (3.16-3.90) 0.0001 4.79 (3.93-5.36) 3.78 (3.21-4.42) 0.0002	FEV ₁ ml (RIC)* 3.94 (3.41-4.38) 2.89 (2.65-3.34) 0.0001 3.91 (3.37-4.38) 2.95 (2.61-3.62) 0.0001	FEV ₁ /FVC (%) 0.81 (0.76-0.84) 0.81 (0.79-0.89) 0.116 0.83 (0.79-0.88) 0.80 (0.78-0.83) 0.049	(ml) 3.95 (3.00-4.66) 3.25 (2.56-3.83) 0.014 4.07 (3.27-4.59) 3.12 (2.53-3.95) 0.0009	 concentrati (ng/ml) Med (P₂₅-P 18.6 (6.2-39 13.6 (7.3-41 0.944 21.4 (5.1-40 15.2 (9.7-38 0.787 44.4 (29.3-46 13.2 (5.1-39
Sex Male Female p value ± Age ≤35 years * >36 year p value ± Job function at the facility Owners/managers	46 29 38 37 8	ml (RIC)* 4.82 (4.23-5.42) 3.48 (3.16-3.90) 0.0001 4.79 (3.93-5.36) 3.78 (3.21-4.42) 0.0002 4.84 (3.47-6.09)	FEV ₁ ml (RIC)* 3.94 (3.41-4.38) 2.89 (2.65-3.34) 0.0001 3.91 (3.37-4.38) 2.95 (2.61-3.62) 0.0001 3.94 (2.66-4.48)	FEV ₁ /FVC (%) 0.81 (0.76-0.84) 0.81 (0.79-0.89) 0.116 0.83 (0.79-0.88) 0.80 (0.78-0.83) 0.049 0.77 (0.72-0.80)	(ml) 3.95 (3.00-4.66) 3.25 (2.56-3.83) 0.014 4.07 (3.27-4.59) 3.12 (2.53-3.95) 0.0009 3.22 (2.19-3.90)	 concentrati (ng/ml) Med (P₂₅-P 18.6 (6.2-39 13.6 (7.3-41 0.944 21.4 (5.1-40 15.2 (9.7-38 0.787 44.4 (29.3-46 13.2 (5.1-39
Sex Male Female p value ± Age ≤35 years * >36 year p value ± Job function at the facility Owners/managers Wait staff/bartenders/cashiers	46 29 38 37 8 53	ml (RIC)* 4.82 (4.23-5.42) 3.48 (3.16-3.90) 0.0001 4.79 (3.93-5.36) 3.78 (3.21-4.42) 0.0002 4.84 (3.47-6.09) 4.42 (3.74-5.17)	FEV ₁ ml (RIC)* 3.94 (3.41-4.38) 2.89 (2.65-3.34) 0.0001 3.91 (3.37-4.38) 2.95 (2.61-3.62) 0.0001 3.94 (2.66-4.48) 3.56 (3.14-4.20)	FEV ₁ /FVC (%) 0.81 (0.76-0.84) 0.81 (0.79-0.89) 0.116 0.83 (0.79-0.88) 0.80 (0.78-0.83) 0.049 0.77 (0.72-0.80) 0.82 (0.79-0.86)	(ml) 3.95 (3.00-4.66) 3.25 (2.56-3.83) 0.014 4.07 (3.27-4.59) 3.12 (2.53-3.95) 0.0009 3.22 (2.19-3.90) 3.94 (3.11-4.59)	Urine cotin concentrati (ng/ml) Med (P ₂₅ -P 18.6 (6.2-39 13.6 (7.3-41 0.944 21.4 (5.1-40 15.2 (9.7-38 0.787 44.4 (29.3-46 13.2 (5.1-39 25.0 (9.7-36 0.08

BMJ Open

7-017811 on 6 October 2017. Downloaded from http://bmjopen.bmj.com/ or

						-	
≤26 hrs*	39	4.05 (3.58-4.75)	3.44 (2.85-3.91)	0.82 (0.78-0.87)	3.81 (2.89-4.59)	11.3 (3.0-26.0	Ž
>27 hrs	36	4.40 (3.45-5.40)	3.64 (2.89-4.32)	0.80 (0.77-0.84)	3.58 (2.78-4.38)	35.8 (11.6-48.	
p value±		0.279	0.457	0.173	0.603	0.0003	
Facility							4
Smoking/mixed	58	4.24 (3.32-5.26)	3.49 (2.85-4.23)	0.81 (0.77-0.84)	3.58 (2.73-4.44)	21.8	50/5
Non-smoking	17	4.24 (3.83-4.55)	3.49 (3.28-3.83)	0.84 (0.80-0.88)	3.98 (3.25-4.48)	21.8 4.1	3
p value ±		0.825	0.845	0.06	0.176	0.0012	ს

*Variable dichotomized in median value; + Kruskal Wallis test; +Wilcoxon Test

Consistent with the literature, sex, age and weight were significantly associated with pulmonary function parameters (Table 4). In terms of job function, the owners and managers had FEV_1/FVC values 60% lower and $FEF_{25/75}$ values 830 ml lower than the group of wait staff, bartenders, and cashiers. The kitchen workers had 700 ml lower FVC values, 640 ml lower FEV₁ values, and 772 ml lower $FEF_{25/75}$ than the group of wait staff, bartenders in smoking facilities had 413 ml lower $FEF_{25/75}$ and 3% lower FEV_1/FVC than workers in non-smoking venues.

 Table 4. Bivariate association of pulmonary function parameters in non-smokers workers

 according to covariables of interest.

_	FVC (ml) FEV_1 (ml) FEV_1/FVC (ml)			FEF _{25/75} (n	FEF _{25/75} (ml)			
_	β (CI95%)	R^2	β (CI95%)	R ²	β (CI95%)	R^2	β (CI95%)	19, R ²
Sociodemographic variables								2024 by
Sex								by
Male	1,260	0.371	0.91	0.321	-0.03	0.053	0.61	guest.
	(0.880 to 1.650)		(0.601 to 1.213)		(-0.064 to -0	.0003)	(0.110 to 1.103)	est.
Age								Pro
	-0.03	0.161	-0.03	0.237	-0.001	0.083	-0.037	<mark>ថ</mark> ្មី 0.189
	(-0.05 to -0.02)		(-0.04 to -0.02)		(-0.003 to -0	.003)	-0.037 (-0.055 to -0.019) ed b
Weight								y ç
	0.04	0.207	0.02	0.154	-0.001	0.056	0.014	PY 0.029
								copyright.

		BMJ	Open					BM
								BMJ Open: first published
								า: first
	(0.02 to 0.05)		(0.01 to 0.04)		(-0.002 to -0.	.0001)	(-0.004 to 0.034	4) b
Size								lishe
	0.08	0.596	0.06	0.595	-0.001	0.009	0.052	
	(0.07 to 0.10)		(0.050 to 0.074)		(-0.002 to 0.0)01)	(0.029 to 0.076	5) s 10
Asthma).11
Yes	0.04 (-0.731 to 0.802)	0.001	-0.17 (-0.750 to 0.422)	0.004	-0.054 (-0.100 to -0.1	0.071	-0.673 (-1.470 to 0.122	26/5
Occupational exposure varia	``´´´		(-0.730 to 0.422)		(-0.100 to -0.	010)	(-1.4/0 10 0.12	⁽⁾ mjo
Job function at the facility	IDIES							pen
Wait staff/bartenders/cashie	ers <i>Ref</i> .	0.097	Ref.	0.104	Ref.	0.1	Ref.	as 10.1136/bmjopen-2017-017811 on 6 October
Owners/managers	0.37		0.003		-0.06		-0.828	7-0
-	(-0.370 to 1.110)		(-0.570 to 0.570)		(-0.113 to -0.	021)	(-1.613 to -0.04	178 (47)
Cooks	-0.7		-0.64		-0.02	021)	-0.772	
COOKS	(-1.290 to -0.120)		(-1.090 to -0.190)		-0.02 (-0.061 to 0.0	1 22)	(-1.391 to -0.1)	ت م
Hours per weekworked	(-1.2)0 to -0.120;		(-1.070 to -0.170)		(-0.001 10 0.0	122)	(-1.571 to -0.1)	O
nouis per weekworken	0.001	0.0003	-0.003	0.003	-0.001	0.034	-0.014	obei
	(-0.02 to 0.02)	0.0002	(-0.02 to 0.01)	0.005	(-0.001 to 0.0		(-0.02 to 0.00	N
U nor weakown agodta SU			(-0.02 10 0.01)		(-0.002 10 0.0	1002)	(-0.02 10 0.00	³ , 17.
Hours per weekexposedto SH	0.01	0.077	0.01	0.046	-0.0004	0.022	0.002	Down
	(0.002 to 0.020)	0.077	(-0.0005 to 0.014)	0.040	-0.0004 (-0.001 to 0.0		0.002 (-0.008 to 0.01 0.028 (-0.021 to 0.07 <i>Ref.</i> -0.413 (-1.003 to 0.17	
Years of work	(0.002 10 0.020)		(-0.0003 to 0.014)		(-0.001 to 0.0	1002)	(-0.000 10 0.01	Judec
I cals of work	-0.01	0.005	-0.001	0.0001	0.003	0.061	0.028	d frō
	(-0.06 to 0.03)		(-0.04 to 0.04)		(0.0003 to 0.0		(-0.021 to 0.0 [°]	3 78) <mark>-</mark>
Facility					[×]	,	× ·	(ttp:/
Non-smoking	Ref.	0.002	Ref.	0.001	Ref.	0.044	Ref.	/bm
Smoking/mixed	0.1		-0.05		-0.03		-0.413	jope
	(-0.460 to 0.672)		(-0.486 to 0.381)		(-0.071 to 0.0)03)	(-1.003 to 0.17	77) <u>5</u> <u>3</u> .

Association between pulmonary function and SHS exposure

The crude model revealed that the association between pulmonary function and urine cotinine concentration was not statistically significant (Table 5). The multivariate analysis was based on a parsimonious model that included the covariate "job function", as this variable was related to pulmonary function and urine cotinine concentration with a p-value<0.10, as well as the variables sex, age, weight, height, and asthma status, all of which are recognized as variables that affect pulmonary function according to SEPAR ^{24, 27}. The

.com/ on April 19, 2024 by guest. Protected by copyright.

adjusted model did not demonstrate a significant relation between urine cotinine concentration and decreased pulmonary function. Conversely, the number of years of SHS exposure in workplace showed an inverse and significant association with FEV₁. Each year of SHS exposure was associated with a 200 ml decrease in FEV₁ (95% CI -0.042 to -0.001). The other pulmonary function variables were also inversely associated with years of SHS exposure in workplace, although the association in these cases did not reach significance. The adjusted model showed an inverse and in some cases statistically significant association between the number of years of SHS exposure and pulmonary function parameters, specifically in FEF _{25/75} (β = -0.006; 95% CI -0.010 to -0.0004).

 Table 5. Crude and adjusted association between pulmonary function parameters and

 SHS exposure of non-smoking workers of bars and restaurants.

	FVC (ml)		FEV ₁ (ml)		FEV ₁ /FVC (n	nl)	FEF25/75 (ml)	
	β (CI95%)	R ²	β (CI95%)	R ²	β (CI95%)	R ²	β (CI95%)	R ²
Urine cotinine					2			
Crude model	0.002	0.002	0.002	0.003	0.0002	0.002	0.002	0.002
	(-0.010 to 0.010)		(-0.010 to 0.010)		(-0.001 to 0.001)		(-0.010 to 0.010)	
Adjusted model	-0.0002	0.781	0.001	0.795	0.0004	0.33	0.005	0.672
	(-0.007 to 0.006)*		(-0.003 to 0.006)*		(-0.0003 to 0.001)+		(-0.006 to 0.015)+	
Number of	years exposed to SHS	5 at work						
Crude model	-0.025	0.0462	-0.022	0.061	-0.0008	0.013	-0.022	0.032
	(-0.051 to 0.002)		(-0.042 to -0.001)		(-0.002 to 0.0008)		(-0,050 to 0,006)	
Adjusted model	-0.013	0.79	-0.01	0.802	0.0006	0.324	-0.006	0.964

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

(-0.030 to 0.0025)* (-0.022 to 0.002)*

*Adjusted by sex, age, weight, size and job function at the facility; + Adjusted by sex, age, size, asthma status and job function at the facility

Discussion

This study is the first in Chile to evaluate occupational SHS exposure and its association with specific pulmonary function parameters. The results indicate that there was an inverse association between the number of years of SHS exposure in workplace and pulmonary function parameters as FEV₁ and FEF _{25/75}. In terms of job function, kitchen workers showed lower pulmonary function values than the group of wait staff, bartenders, and cashiers as compared to the owners and managers. One possible explanation for these findings is that the SHS exposure had an additive effect with exposure to other pollutants emitted in the kitchen. In the literature has been reported that workers in kitchens with gas stoves show lower pulmonary function parameters than those in kitchens with electric stoves, due to greater exposure to toxic substances in the air after cooking with gas ²⁸. In our study, it was not possible to analyze differences according this variable because 100% of the establishments used gas stoves.

Although the present study was not able to find a significant association between FVC and urine cotinine concentration a trend can be observed. A possible explanation for these results is the use of urine cotinine concentration as biomarker of exposure. As noted above, urine cotinine levels reflect recent exposure to tobacco smoke^{16, 17, 26} while chronic exposure to SHS is likely implicated in a decline in pulmonary function parameters. In fact, analysis of the exposure variable *number of years of SHS exposure in workplace* (including the 3 most recent job positions) did reveal significant associations between SHS exposure

BMJ Open: first published as 10.1136/bmjopen-2017-017811 on 6 October 2017. Downloaded from http://bmjopen.bmj.com/ on April 19, 2024 by guest. Protected by copyright

and FEV₁ (β = -0.022; 95% CI -0.042 to -0.001) and FEF_{25/75} (β = -0.006; 95% CI -0.010 to -0.0004), suggesting that this variable is useful in studies of cumulative SHS exposure. It should also be noted that our sample included mainly young workers being reasonable to infer that the sample not accumulated sufficient years of SHS exposure to register significant changes in pulmonary function. Other studies that have addressed this topic have produced varying results^{11, 12, 13, 16, 17, 26, 29, 30} reported a significant inverse association between SHS exposure (evaluated through self-report) and FVC and FEV₁. In our study, self-reported SHS exposure measured in *hours per week* was inversely correlated with FEV₁/FVC and FEF₂₅₋₇₅, but the association did not reach significance. As in our study, Chen et al. did not find a significant association when serum cotinine was assess as exposure variable, but did when exposure to SHS was measured through self-report¹².

A possible limitation of this study was that the median time worked at the location was only about 1 year. About 25% of the sample had worked at the given facility for less than 3 months, and 75% of the sample had worked at the location for fewer than 2 years. This condition of high turnover rate, along with the relative youth of the workers contributes to assume that the sample not accumulated enough years of SHS exposure to register significant changes in pulmonary function.

Another potential limitation was the timing of the spirometry measurements. The literature reports that pulmonary function varies throughout the day according to circadian rhythm, decreasing from a high point in the early morning until about noon and then rising again to peak between about 4 and 5 in the afternoon. These daily fluctuations may have affected

the results, as the lung function measurements were performed at various times of day, according to the availability and shifts of the workers and establishments.

While this study did not find a significant association between years of SHS exposure in workplace and urine cotinine concentration (β =0.060, p-value=0.264; R²=0.017) there was a significant association between weekly hours of exposure and urine cotinine (β = 0.365, p-value<0.001; R²=0.24). This finding suggests that a self-reported weekly hour of exposure is an acceptable qualitative biomarker of recent exposure if quantitative measurements are not available.

Conclusion

The years of exposure to SHS in workplace as proxy of chronic exposure were inverse and significantly associated with the $FEF_{25/75}$, and inverse but not significant with FVC and FEV_1 . These findings suggest that cumulative exposure to SHS at work may contribute to deterioration of pulmonary function in non-smoking employees.

Acknowledgments

The authors would like to thank to employees, managers and venue owners who agreed to participate in this study. Also to the Department of Research of the Universidad de Los Andes-Chile for the support given to translate this article.

Competing interest

The authors have no conflict of interest to declare.

Funding

This study was supported by National Fund for Research and Development in Health FONIS, CONICYT – MINSAL, Research Grant # SA09I062 and by International Training and Research in Environmental and Occupational Health (ITREOH), Fogarty International Center, NIH Research Grant #D43TW005746-02.

References

1. Alwan A. World Health Organization. 2009. WHO Report on the Global Tobacco Epidemic. Implementing smoke-free environments; [Cited 2016 Jun 24]. Available from: http://who.int/tobacco/mpower/2009/gtcr_download/en/index.html

Bello Sergio, Michalland Susana, Soto Marina, Contreras Carla, Salinas Judith. 2005.
 Effects in passive smokers of environmental tobacco smoke exposure. *Rev Chil Enf Respir* 21:179-192.

3. Chan-Yeung Moira, Dimich-Ward Helen. 2003. Respiratory health effects of exposure to environmental tobacco smoke. *Respirology* 8(2):131-139.

4. Collishaw Neil E, Kirkbride John, Wigle Donald. 1984. Tobacco smoke in the workplace: an occupational health hazard. *Can Med Assoc J* 131(10):1191-1204.

5. Aceituno Paulina, Iglesias Verónica, Erazo Marcia, Droppelmann Andrea, Orellana Cecilia, Navas-Acién Ana. 2010. The work environment as a source of exposure to secondhand smoke: a study in workers of bars and restaurants of Santiago, Chile. *Rev Med Chile* 138:1517-1523.

6. Coultas David. 1998. Health effects of passive smoking. Passive smoking and risk of adult asthma and COPD: an update. *Thorax* 53(5):381-387.

7. De Vito Eduardo, Rojas Ramón. 2005. Environmental tobacco smoke. *Medicina (B. Aires)* 65(6):545-549.

8. Jaakkola Maritta, Jaakkola Jouni, Becklake Margaret, Ernst Pierre. 1995. Passive smoking and evolution of lung function in young adults. An 8-year longitudinal study. *J Clin Epidemiol* 48(3):317-327.

9. Jayet Pierre-Yves, Schindler Christian, Schwartz Joel, Kunzli Nino, Zellweger Pierre, Ackermann-Liebrich Ursula, Leuenberger Phillippe. 2005. Passive smoking exposure among adults and the dynamics of respiratory symptoms in a prospective multicenter cohort study. *Scand J Work Environ Health* 31(6):465-473.

10. Rizzi Maurizio, Sergi Margherita, Andreoli Arnaldo, Pecis Marica, Bruschi Claudio, Fanfulla Francesco. 2004. Environmental tobacco smoke may induce early lung damage in healthy male adolescents. *Chest* 125(4):1387-1393.

11. Alipour Shahryar, Deschamps Frédéric, Lesage FranÇois-Xavier. 2005. Effects of Environmental Tobacco Smoke on Respiratory Symptoms and Pulmonary Function. *Inhal Toxicol* 18(8):569-573.

12. Chen Ruoling, Tunstall-Pedoe H, Tavendale R. 2001. Environmental tobacco smoke and lung function in employees who never smoked: the Scottish MONICA study. *Occup Environ Med* 58(9):563-568.

13. Fidan F, Cimrin AH, Ergor G, Sevinc C. 2004. Airway disease risk from environmental tobacco smoke among coffeehouse workers in Turkey. *Tob Control* 13(2):161-6.

14. Janson Christer, Chinn Susan, Jarvis Deborah, Zock Jan-Paul, Torén Kjell, Burney Peter. 2001. Effects of passive smoking on respiratory symptoms, bronchial

BMJ Open

responsiveness, lung function, and total serum IgE in the European Community Respiratory Health survey: a cross sectional study. *Lancet* 358(2):103-109.

15. Eisner Mark D. 2002. Environmental tobacco smoke exposure and pulmonary function among adults in NHANES III: impact on the general population and adults with current asthma. *Environ Health Perspect* 110(8):765-70.

16. Benowitz Neal L. 1999. Biomarkers of environmental tobacco smoke exposure. *Environ Health Perspect* 107(2):349-55.

17. Tutka Piotr, Mosiewicz Jerzy, Wielosz Marian. 2005. Pharmacokinetics and metabolism of nicotine. *Pharmacol Rep* 57(2):143-53.

18. Centers for Disease Control and Prevention. 2017. National Report of Human Exposure
to Environmental Chemicals; [Cited 2017 March 15]. Available from:
https://www.cdc.gov/exposurereport/

19. Al-Delaimy WK, Crane J, Woodward A. 2000. Questionnaire and hair measurement of exposure to tobacco smoke. *J Expo Anal Environ Epidemiol* 10:378-384.

20. Al-Delaimy WK. 2002. Hair as a biomarker for exposure to tobacco smoke. *Tob Control* 11:176-182.

21. Iglesias Verónica, Erazo Marcia, Droppelmann Andrea, Steenland Kyle, Aceituno Paulina, Orellana Cecilia, Acuña Marisol, Peruga Armando, Breysse Patrick N, Navas-Acien Ana. 2014. Occupational secondhand smoke is the main determinant of hair nicotine concentrations in bar and restaurant workers. *Environ Res* 132:206–211.

22. Salud OMS. 2003. "Convenio Marco de la OMS para el control del tabaco"; [Cited 2016 Jun 24]. Available from: http://www.who.int/fctc/text_download/es/.

23. Muñoz Claudio, Droppelmann Andrea, Erazo Marcia, Aceituno Paulina, Orellana Cecilia, Parro Javiera, Mesias Stephanie, Marchetti Nella, Navas-Acien Ana, Iglesias Verónica. 2016. Occupational exposure to polycyclic aromatic hydrocarbons: A cross-sectional study in bars and restaurants in Santiago, Chile. *Am J Ind Med*. Version of record online: 28 Jun 2016.

24. Burgos Felipe, Casan Pere, Del Campo Félix, Gáldiz Juan, Giner Jordi, González-Mangado Nicolás, Ortega Francisco, Puente Luis, García Francisco, Calle Myriam. SEPAR Regulation: Forced Spirometry. 2013; [Cited 2016 Jun 24]. Available from: http://www.ics.gencat.cat/3clics/guies/184/img/--guiasepar20131.pdf

25. Gutiérrez C. Mónica, Beroíza Teresa, Barzone Gisella, Caviedes Iván, Céspedes Iván, Céspedes Juan, Gutiérrez N. Mónica, Moreno Rodrigo, Oyarzún Manuel, Palacios Sylvia, Schonffeldt Patricia. 2007. Spirometry: Procedures Manual. Chilean Society of Respiratory Diseases, 2006. *Rev Chil Enf Respir* 23:31-42.

26. Vine Marilyn, Hulka Barbara, Margolin Barry, Truong Young, Hu Ping-chuan, Schramm Margaret, Griffith Jack, McCann Margaret, Everson Richard. 1993. Cotinine Concentrations in Semen, Urine, and Blood of Smokers and Nonsmokers. *Am J Public Health* 83(9):1335-1338.

27. Tong Shilu, Lu Ying. 2001. Identification of confounders in the assessment of the relationship between lead exposure and child development. *Ann Epidemiol* 11(1): 38-45.

BMJ Open

28. Wong Tze Wai, Wong Andromeda H, Lee Frank S, Qiu Hong. 2011. Respiratory health and lung function in Chinese restaurant kitchen workers. *Occup Environ Med* 68(10):746-752.

29. Kunzli N, Schwartz J, Stutz EZ, Ackermann-Liebrich U, Leuenberger P. 2000. Association of environmental tobacco smoke at work and forced expiratory lung function among never smoking asthmatics and non-asthmatics. The SAPALDIA-Team. Swiss Study on Air Pollution and Lung Disease in Adults. *Soz Praventivmed* 45(5):208-17.

30. Skogstad M, Kjaerheim K, Fladseth G, Gjølstad M, Daae HL, Olsen R, Molander P, Ellingsen DG. 2006. Cross shift changes in lung function among bar and restaurant workers before and after implementation of a smoking ban. *Occup Environ Med* 63:482-487.



BMJ Open: first published as 10.1136/bmjopen-2017-017811 on 6 October 2017. Downloaded from http://bmjopen.bmj.com/ on April 19, 2024 by guest. Protected by copyright

Contributorship statement

Parro Javiera. Substantial contributions to the conception and design of the work on pulmonary function parameters; acquisition, analysis and interpretation of data, drafting the work, and final approval of the version to be published;

Aceituno Paulina. Substantial contributions to the conception and design of the work, revising it critically for important intellectual content, final approval of the version to be published.

Droppelman Andrea. Substantial contributions to the conception, design of the work and interpretation of exposure data, final approval of the version to be published.

Mesías Sthepanie. Substantial contributions to the acquisition and analysis of exposure data, final approval of the version to be published.

Muñoz Claudio. Substantial contributions to the acquisition, analysis and interpretation of data, final approval of the version to be published.

Marchetti Nella. Substantial contributions to the conception of the work and interpretation of data, final approval of the version to be published.

Iglesias Verónica. Substantial contributions to the conception and design of the work, analysis and interpretation of data for the work; drafting the work, final approval of the version to be published, agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

BMJ Open

STROBE Statement—checklist of items that should be included in reports of observational studies

	Item No	Recommendation
Title and abstract	1	(<i>a</i>) Indicate the study's design with a commonly used term in the title or the abstract YES
		(b) Provide in the abstract an informative and balanced summary of what was done
		and what was found <mark>YES</mark>
Introduction		
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported YES
Objectives	3	State specific objectives, including any prespecified hypotheses YES
Methods		
Study design	4	Present key elements of study design early in the paper YES
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment,
	•	exposure, follow-up, and data collection YES
Participants	6	(a) Cohort study—Give the eligibility criteria, and the sources and methods of
		selection of participants. Describe methods of follow-up
		Case-control study—Give the eligibility criteria, and the sources and methods of
		case ascertainment and control selection. Give the rationale for the choice of cases
		and controls
		<i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of
		selection of participants YES
		(b) Cohort study—For matched studies, give matching criteria and number of
		exposed and unexposed
		Case-control study—For matched studies, give matching criteria and the number of
		controls per case
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect
		modifiers. Give diagnostic criteria, if applicable YES
Data sources/	8*	For each variable of interest, give sources of data and details of methods of
measurement		assessment (measurement). Describe comparability of assessment methods if there
		is more than one group YES
Bias	9	Describe any efforts to address potential sources of bias YES
Study size	10	Explain how the study size was arrived at YES
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable,
		describe which groupings were chosen and why YES
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding
		(b) Describe any methods used to examine subgroups and interactions
		(c) Explain how missing data were addressed
		(d) Cohort study—If applicable, explain how loss to follow-up was addressed
		<i>Case-control study</i> —If applicable, explain how matching of cases and controls was
		addressed
		<i>Cross-sectional study</i> —If applicable, describe analytical methods taking account of sampling strategy YES

For beer review only

Results Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible,
Farticipants	13	examined for eligibility, confirmed eligible, included in the study, completing follow-up, and
		analysed YES
		(b) Give reasons for non-participation at each stage YES
		(c) Consider use of a flow diagram NO
Descriptive	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information
data		on exposures and potential confounders YES
		(b) Indicate number of participants with missing data for each variable of interest YES
		(c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount)
Outcome data	15*	Cohort study—Report numbers of outcome events or summary measures over time
		Case-control study—Report numbers in each exposure category, or summary measures of
		exposure YES
		Cross-sectional study—Report numbers of outcome events or summary measures YES
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their
		precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and
		why they were included YES
		(b) Report category boundaries when continuous variables were categorized YES
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful
		time period NO
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity
		analyses NO
Discussion		
Key results	18	Summarise key results with reference to study objectives YES
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision.
		Discuss both direction and magnitude of any potential bias YES
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity
		of analyses, results from similar studies, and other relevant evidence YES
Generalisability	21	Discuss the generalisability (external validity) of the study results YES
Other information	on	
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable,
		for the original study on which the present article is based YES

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at www.strobe-statement.org.

BMJ Open: first published as 10.1136/bmjopen-2017-017811 on 6 October 2017. Downloaded from http://bmjopen.bmj.com/ on April 19, 2024 by guest. Protected by copyright

BMJ Open

Secondhand tobacco smoke exposure and pulmonary function: a cross-sectional study among non-smoking employees of bar and restaurants in Santiago, Chile

Journal:	BMJ Open
Manuscript ID	bmjopen-2017-017811.R1
Article Type:	Research
Date Submitted by the Author:	27-Jul-2017
Complete List of Authors:	Parro, Javiera; Universidad de Los Andes, Facultad de Enfermería Aceituno, Paulina; Universidad de Chile, Facultad de Medicina, Escuela de Salud Pública Droppelmann, Andrea; Instituto de Salud Pública, Laboratorio de Salud Ocupacional Mesías, Sthepanie; Universidad de Chile, Facultad de Medicina, Escuela de Salud Pública muñoz, claudio; Universidad de La Frontera, Facultad de Medicina Marchetti, Nella; Universidad de Chile, Facultad de Medicina, Escuela de Salud Pública Iglesias, Verónica; Universidad de Chile, Facultad de Medicina, Escuela de Salud Pública
Primary Subject Heading :	Occupational and environmental medicine
Secondary Subject Heading:	Smoking and tobacco
Keywords:	OCCUPATIONAL & INDUSTRIAL MEDICINE, RESPIRATORY MEDICINE (see Thoracic Medicine), Chronic airways disease < THORACIC MEDICINE

SCHOLARONE[™] Manuscripts

BMJ Open

Secondhand tobacco smoke exposure and pulmonary function: a cross-sectional study among non-smoking employees of bar and restaurants in Santiago, Chile.

Javiera Parro. Escuela de Enfermería, Universidad de Los Andes. Santiago, Chile.

Paulina Aceituno. Escuela de Salud Pública, Facultad de Medicina, Universidad de Chile. Santiago, Chile.

Andrea Droppelmann. Laboratorio de Salud Ocupacional, Instituto de Salud Pública. Santiago, Chile.

Sthepanie Mesías. Escuela de Salud Pública, Facultad de Medicina, Universidad de Chile. Santiago, Chile.

Claudio Muñoz. Facultad de Medicina, Universidad de La Frontera. Temuco, Chile.

Nella Marchetti. Escuela de Salud Pública, Facultad de Medicina, Universidad de Chile.

Santiago, Chile.

Verónica Iglesias, Escuela de Salud Pública, Facultad de Medicina, Universidad de Chile.

Santiago, Chile.

Corresponding author:

Verónica Iglesias Alamos.

Postal address: Independencia 939, Independencia, Santiago Chile, 8380453.

Email: viglesia@med.uchile.cl.

Telephone number: 56-229786397.

Word count: 2.703

Abstract

Introduction. The workplace remains a significant source of secondhand smoke (SHS) exposure. This pollutant is known to be associated with respiratory and cardiovascular problems, but its effects on specific pulmonary function parameters remain largely unexplored. The objectives of this study were to measure SHS exposure among non-smoking employees of bar and restaurants in Santiago, Chile and to evaluate the effects of such exposure on pulmonary function.

Methods. Cross-sectional design. The study sample included non-smoking workers from 57 restaurants and bars in Santiago, Chile. The outcome variable was pulmonary function and the exposure variables were urine cotinine concentration, a biomarker for current SHS exposure, and years of SHS exposure in the workplace as proxy of chronic exposure. Personal and occupational variables were also recorded. Data analysis was performed using linear regression models adjusted by confounders.

Results. The median age of the workers was 35 years and the median employment duration at the analysed venues was 1 year. Workers in smoking facilities reported greater SHS exposure (36 hours per week) than workers in smoke-free locations (4 hours per week). Urine cotinine levels were inversely correlated with forced vital capacity (FVC), but the finding was not statistically significant (β =-0.0002; 95% CI: -0.007 to 0.006). Years of exposure to SHS showed to be significantly associated with FEF25 / 75 (β = -0.006; 95% CI: -0.010 to -0.0004).

Conclusion. These findings suggest that cumulative exposure to SHS at work may contribute to deterioration of pulmonary function in non-smoking employees.

BMJ Open: first published as 10.1136/bmjopen-2017-017811 on 6 October 2017. Downloaded from http://bmjopen.bmj.com/ on April 19, 2024 by guest. Protected by copyright

cotinine, workers. Strengths and limitations of this study - The effects of occupational SHS exposure on specific pulmonary function parameters has been scarcely explored. - This study is the first in Chile to evaluate occupational SHS exposure and its association with specific pulmonary function parameters. - The use of the variable "number of years exposed to SHS at workplace" was appropriate to studied chronic SHS exposure. - Our sample included mainly young workers being reasonable to infer that the sample not accumulated sufficient years of SHS exposure to register greater changes in pulmonary

- Daily fluctuations of the timing of the spirometry measurements may have affected the results, since these were performed at various times of day, according to the availability and shifts of the workers and establishments.

Introduction

function.

The secondhand smoke (SHS) is the smoke that remains in the air after someone has consumed tobacco, including the smoke coming from the burning end of the cigarette (sidestream smoke) and the smoke exhaled by the smoker (mainstream smoke) 1, 2, 3, 4, 5. Exposure to side-stream smoke is more harmful than exposure to mainstream smoke as it contains a greater amount of toxic gases and smaller particles that reach greater depth in the

lungs when inhaled ⁶. SHS is a common indoor pollutant in restaurants and bars that poses a serious health risk for non-smokers as it contains over 50 substances known to be carcinogenic in humans ^{7, 8}. There is no known safe exposure level ^{1, 4}. Some of the highest and most sustained occupational exposure to SHS occur in bar staff, with non-smoking areas providing only limited protection ⁹.

SHS exposure can lead to the same health problems associated with active smoking ^{1, 7, 8}, with risk levels increasing as a function of hours of exposure ^{10, 11, 12, 13, 14}. Common scenarios associated with chronic SHS exposure include living with a spouse or parent who smokes and working in a location where smoking is allowed ^{3, 5}. Previous studies have not been consistent in showing a decline in specific pulmonary function parameters in people affected by SHS exposure at work or at home ^{9, 15, 16, 17, 18, 19, 20}. This lack of evidence may be attributable to the methods use to measure SHS exposure, which range from self-report to measurement of exposure biomarkers ^{15, 16, 17, 18, 19}.

One of the most common ways of measuring SHS exposure is measuring concentration of cotinine, the principle metabolite of nicotine. Cotinine can be measured in the blood or urine and shows high sensitivity and specificity for acute SHS exposure (over the past 3–4 days), although some authors have also used it to evaluate longer-term exposure ^{21, 22, 23}. Chronic exposure to SHS has been measured through questionnaire and by hair nicotine concentration ^{24, 25}.

In 2010, the time at which this study was performed, Chilean law prohibited tobacco smoking in public areas and workplaces. However, there were exceptions for "hospitality" venues, such as casinos, bars, pubs, restaurants, and cafés. Bars, pubs, and restaurants with areas smaller than 100 m^2 could choose to allow smoking indoors or not, while facilities

BMJ Open

with an area larger than 100 m^2 were required to offer separate sections for smokers and nonsmokers. Therefore, "hospitality" workers were unprotected from SHS exposure, becoming the workplace, in many cases, the main source of SHS exposure ^{26, 27}.

The objectives of this study were to measure SHS exposure among non-smoking workers in restaurants and bars in Santiago, Chile and to evaluate the effects of such exposure on pulmonary function.

Methods

This cross-sectional study was performed as part of a larger project, "Impact of involuntary exposure to tobacco smoke on respiratory health: study of pub and restaurant workers", carried out in Santiago, Chile between September 2010 and January 2011. This study was approved by the University of Chile School of Medicine's Ethics Committee.

Population and sample

The selection process for participating facilities has been previously described in detail ²⁸. In brief, the sampling framework included the 5 municipalities with the largest numbers of facilities, according to data provided by the National Institute of Statistics (Spanish acronym INE, for *Instituto Nacional de Estadísticas*). Study staff visited 690 locations and used a brief survey to record the venue's name, address, type of facility (bar/pub, restaurant, or other), smoking status (smoking allowed in all areas; designated smoking/non smoking areas; or smoke-free), and number of non-smoking workers. Of the 690 facilities, 207 met inclusion criteria (be a bar-pub or restaurant and have non-smoking workers). Of them, 108 were visited or contacted by telephone to invite the owner or manager to participate in the study. In 63 establishments they agreed to participate (58%). For logistical reasons, only 59 of the facilities were included ²⁸. Smoking and non-smoking workers in these facilities were

invited to participate in the main study. Only those who had not smoked in the last year were included in the current study. Workers were excluded if they did not provide a urine sample (n=5) or had a contraindication for spirometry (n=1) $^{29, 30}$.

Outcome variables

Pulmonary function parameters: Certified personnel used an *Easy One Diagnostic*[®] to measure forced vital capacity (FVC) and forced expiratory volume in 1s (FEV₁), and then calculated the FEV₁ to FVC ratio (FEV₁/FVC) and forced expiratory flow as 25%–75% of FVC (FEF₂₅₋₇₅). Spirometry measurements were performed during working hours. In compliance with international norms on collecting and interpreting spirometry data, age, sex, weight, height, and race of each participant were also recorded ^{29, 30}. A maximum of 8 spirometry trials were performed. The criteria for including a participant's spirometry data in the analysis was achieving at least 3 acceptable and 2 reproducible trials, as described in the norms published by Spanish Society of Pneumology and Thoracic Surgery (Spanish acronym SEPAR, for *Sociedad Española de Neumología y Cirugía Torácica*) ^{29, 30}. The equipment was calibrated weekly.

Exposure variables

Urine cotinine concentration. Each worker was asked to provide urine sample the morning after the spirometry measurements. The sample was provided, retrieved, and frozen on the same day. Urine cotinine concentration was measured using ELISA at a sensitivity of 1 ng/ml. The cut-off value typically used in the literature to distinguish smokers from non-smokers is 10 ng/ml³¹. As a quality control, duplicate samples were obtained and analyzed. There was a strong correlation between the original and duplicate samples (Spearman's correlation=0.96; p-value=0.0005). Chronic exposure to SHS was measured as *the number*

BMJ Open

of years exposed to SHS at workplace (number of years worked at their 3 most recent job positions and whether it involved SHS exposure).

Covariables

The questionnaire included items about the participant's health history (asthma diagnosis, smoking habits); occupational history (job function at the facility, secondary employment at another facility, number of hours per day and days per week worked); occupational exposure (number of hours per day and days per week exposed to SHS); and the type of facility (smoking, mixed, or non-smoking).

Statistical analysis

Data analysis was performed using the program STATA 12. The quantitative variables were assessed for normality using the Shapiro-Wilk test. Descriptive statistics were calculated, including median and interquartile ranges (P_{25} – P_{75}) for quantitative variables and relative frequency for qualitative variables. Quantitative exposure variables and covariables, such as number of hours per week of SHS exposure or age were dichotomized using the median as cutoff. Kruskal Wallis test and Wilcoxon test were used to assess difference of pulmonary parameters and exposure variables between the categories of the covariables. Finally, the association between pulmonary function parameters and exposure to SHS was analyzed using multiple linear regression models adjusted by covariates potentially associated with both, the outcome and the exposure considering a p-value of<0.10 ³², as well as variables commonly controlled for in the literature.

Results

The non-smoking workers evaluated in the study were 92. 17(18.5%) were excluded due to spirometry results failed to meet the criteria for acceptability and reproducibility. The final

sample was 75 workers. Median age wa	s 35 years	(P ₂₅ -P ₇₅ : 19-	-68 years), a	nd 61% of				
participants were male. 29.3% were former smokers and the median of time they quit								
smoking was 8.5 years (RIC 2 to 15 years). They were homogeneously distributed at the								
different facility type. On average, participants had worked at the studied venue for 12								
months. Independent of the facility type, t	-							
	-	-	-	-				
bartenders, and cashiers (58.7%) followed	by owners	or managers	(28%), and find	nally cooks				
(13.3%). Workers in smoking facilities rep	ported highe	er number of v	weekly hours	exposed to				
SHS compared to workers in mixed and no	on-smoking	facilities (p-v	alue=0.0001)	(Table 1).				
Table 1. Characteristics of the study sample	-			. /				
Table 1. Characteristics of the study sample	r. Sanuago, (
		Smoking st	atus restaurant/h					
	Total	Smoking	Mixed	Non-smoking	p value			
N° employees n (%)	Total 75 (100)	Smoking 27 (36.0)	Mixed 31 (41.3)	Non-smoking 17 (22.7)	p value			
Sociodemographic characteristics	75 (100)	27 (36.0)	31 (41.3)	17 (22.7)				
Sociodemographic characteristics Age, Median (P ₂₅ -P ₇₅)		-		0	p value 0.081*			
Sociodemographic characteristics	75 (100)	27 (36.0)	31 (41.3)	17 (22.7)				
Sociodemographic characteristics Age, Median (P ₂₅ -P ₇₅) Sex, n (%)	75 (100) 35.0 (19.0-62)	27 (36.0) 40.0 (29.0-52.0)	31 (41.3) 35.0 (21.0-57.0)	17 (22.7) 31.0 (22.0-44.0)	0.081*			
Sociodemographic characteristics Age, Median (P ₂₅ -P ₇₅) Sex, n (%) Male	75 (100) 35.0 (19.0-62)	27 (36.0) 40.0 (29.0-52.0)	31 (41.3) 35.0 (21.0-57.0)	17 (22.7) 31.0 (22.0-44.0)	0.081*			
Sociodemographic characteristics Age, Median (P ₂₅ -P ₇₅) Sex, n (%) Male Asthma, n (%)	75 (100) 35.0 (19.0-62) 46 (61.3)	27 (36.0) 40.0 (29.0-52.0) 17 (63.0)	31 (41.3) 35.0 (21.0-57.0) 19 (61.3)	17 (22.7) 31.0 (22.0-44.0)	0.081*			
Sociodemographic characteristics Age, Median (P ₂₅ -P ₇₅) Sex, n (%) Male Asthma, n (%) Yes	75 (100) 35.0 (19.0-62) 46 (61.3) 8 (10.7)	27 (36.0) 40.0 (29.0-52.0) 17 (63.0) 1 (3.7)	31 (41.3) 35.0 (21.0-57.0) 19 (61.3) 7 (22.6)	17 (22.7) 31.0 (22.0-44.0) 10 (59.0) -	0.081*			
Sociodemographic characteristics Age, Median (P ₂₅ -P ₇₅) Sex, n (%) Male Asthma, n (%) Yes No	75 (100) 35.0 (19.0-62) 46 (61.3) 8 (10.7)	27 (36.0) 40.0 (29.0-52.0) 17 (63.0) 1 (3.7)	31 (41.3) 35.0 (21.0-57.0) 19 (61.3) 7 (22.6)	17 (22.7) 31.0 (22.0-44.0) 10 (59.0) -	0.081*			
Sociodemographic characteristics Age, Median (P ₂₅ -P ₇₅) Sex, n (%) Male Asthma, n (%) Yes No Occupational exposure	75 (100) 35.0 (19.0-62) 46 (61.3) 8 (10.7)	27 (36.0) 40.0 (29.0-52.0) 17 (63.0) 1 (3.7)	31 (41.3) 35.0 (21.0-57.0) 19 (61.3) 7 (22.6)	17 (22.7) 31.0 (22.0-44.0) 10 (59.0) -	0.081*			
Sociodemographic characteristics Age, Median (P ₂₅ -P ₇₅) Sex, n (%) Male Asthma, n (%) Yes No Occupational exposure Job function at the facility, n (%)	75 (100) 35.0 (19.0-62) 46 (61.3) 8 (10.7) 67 (89.3)	27 (36.0) 40.0 (29.0-52.0) 17 (63.0) 1 (3.7) 26 (96.3)	31 (41.3) 35.0 (21.0-57.0) 19 (61.3) 7 (22.6) 24 (77.4)	17 (22.7) 31.0 (22.0-44.0) 10 (59.0) - 17 (100)	0.081*			
Sociodemographic characteristics Age, Median (P ₂₅ -P ₇₅) Sex, n (%) Male Asthma, n (%) Yes No Occupational exposure Job function at the facility, n (%) Owners/managers	75 (100) 35.0 (19.0-62) 46 (61.3) 8 (10.7) 67 (89.3) 21 (28.0)	27 (36.0) 40.0 (29.0-52.0) 17 (63.0) 1 (3.7) 26 (96.3) 7 (25.9)	31 (41.3) 35.0 (21.0-57.0) 19 (61.3) 7 (22.6) 24 (77.4) 1 (3.2)	17 (22.7) 31.0 (22.0-44.0) 10 (59.0) - 17 (100) 13 (76.5)	0.081* 0.963** 0.018**			
Sociodemographic characteristics Age, Median (P ₂₅ -P ₇₅) Sex, n (%) Male Asthma, n (%) Yes No Occupational exposure Job function at the facility, n (%) Owners/managers Wait staff/bartenders/cashiers	75 (100) 35.0 (19.0-62) 46 (61.3) 8 (10.7) 67 (89.3) 21 (28.0) 44 (58.7)	27 (36.0) 40.0 (29.0-52.0) 17 (63.0) 1 (3.7) 26 (96.3) 7 (25.9) 13 (48.2)	31 (41.3) 35.0 (21.0-57.0) 19 (61.3) 7 (22.6) 24 (77.4) 1 (3.2) 27 (87.1)	17 (22.7) 31.0 (22.0-44.0) 10 (59.0) - 17 (100) 13 (76.5)	0.081* 0.963** 0.018**			
Sociodemographic characteristics Age, Median (P ₂₅ -P ₇₅) Sex, n (%) Male Asthma, n (%) Yes No Occupational exposure Job function at the facility, n (%) Owners/managers Wait staff/bartenders/cashiers Cooks	75 (100) 35.0 (19.0-62) 46 (61.3) 8 (10.7) 67 (89.3) 21 (28.0) 44 (58.7) 10 (13.3)	27 (36.0) 40.0 (29.0-52.0) 17 (63.0) 1 (3.7) 26 (96.3) 7 (25.9) 13 (48.2) 7 (25.9)	31 (41.3) 35.0 (21.0-57.0) 19 (61.3) 7 (22.6) 24 (77.4) 1 (3.2) 27 (87.1) 3 (9.7)	17 (22.7) 31.0 (22.0-44.0) 10 (59.0) - 17 (100) 13 (76.5) 4 (23.5) -	0.081* 0.963** 0.018** 0.005**			

Page 9 of 26

BMJ Open

As shown in Table 2 we compared the results for pulmonary function and exposure to SHS based on covariables. Males had greater pulmonary function values than females, except for FEV₁/FVC ratio, where no differences were observed. No differences in pulmonary function were observed between former smokers and never smokers groups. In terms of the occupational exposure variables, employees working in the kitchen had lower values for FVC, FEV_1 , and $FEF_{25/75}$ than the group of wait staff, bartenders, cashiers, and managers. Regarding the number of hours per week of SHS exposure and pulmonary function, exposure greater than 26 hours per week was associated with a 0.02% decrease in FEV_1/FVC and a 230 ml decrease in $FEF_{25/75}$ although these results were not statistically significant. Workers in smoking venues had FEF_{25/75} 400 ml lower and FEV₁/FVC ratios 0.03% lower than those of workers in non-smoking venues. In terms of urine cotinine concentration, owners and managers had the highest levels, followed by kitchen workers and then finally the group of wait staff, bartenders, and cashiers (44.4 ng/ml, 25.0 ng/ml, and 13.2 ng/ml, respectively). Urine cotinine concentration varied by number of hours per week of SHS exposure as self-reported by participants and by the smoking status of the facility. Workers with over 26 hours per week of SHS exposure had urine cotinine values 24.5 ng/ml higher than those who reported 26 or fewer hours of exposure per week, while workers in smoking facilities show levels of urine cotinine 17.7 ng/ml higher than workers in non-smoking facilities. The number of years exposed to SHS workplace varied according to sex, age and smoking status of employees.

Table 2. Pulmonary function and exposure to secondhand smoke at non-smoking workers.

Santiago, 2010-2011.

1

Santiago, 2	2010-	2011.					
Variables			Pulmonary fund	ction parameters		Urine cotinine	Number of year
0 1	n	FVC	FEV ₁	FEV ₁ /FVC	FEF 25%/75%	concentration (ng/ml)	exposed to SH workplace
2 3		ml (RIC)	ml (RIC)	% (RIC)	ml (RIC)	Med (P ₂₅ -P ₇₅)	Med (P ₂₅ -P ₇₅
tex 5							
6Male 7	46	4.82 (4.23-5.42)	3.94 (3.41-4.38)	0.81 (0.76-0.84)	3.95 (3.00-4.66)	18.6 (6.2-39.5)	3.5 (1.0-11.3)
8Female	29	3.48 (3.16-3.90)	2.89 (2.65-3.34)	0.81 (0.79-0.89))	3.25 (2.56-3.83)	13.6 (7.3-41.1)	1.0 (0.16-4.0)
9 O ^p value ± 1		0.0001	0.0001	0.116	0.014	0.944	1.0 (0.16-4.0 0.01 1.0 (0.25-5.0
1 _{ge} * 2							
3≤35 years 4	38	4.79 (3.93-5.36)	3.91 (3.37-4.38)	0.83 (0.79-0.88)	4.07 (3.27-4.59)	21.4 (5.1-40.7)	
5>36 year	37	3.78 (3.21-4.42)	2.95 (2.61-3.62)	0.80 (0.78-0.83)	3.12 (2.53-3.95)	15.2 (9.7-38.1)	4.0 (1.0-11.7
6 7p value ±		0.0002	0.0001	0.049	0.0009	0.787	0.02
8 Smoking status 9							
0 _{Never smokers}	53	4.23 (3.45-4.89)	3.49 (2.88-4.06)	0.81 (0.79-0.86)	3.69 (2.85-4.39)	21.7 (5.7-43.8)	1.0 (0.75-5.0
2Former smokers	22	4.33 (3.58-5.32)	3.53 (2.99-4.26)	0.81 (0.76-0.85)	3.77 (3.0-4.59)	12.9 (9.4-36.8)	6.3 (0.83-11.7
3 4p value ±		0.767	0.684	0.452	0.907	0.629	0.04
5 ob function at the facility							
7 Owners/managers 8	8	4.84 (3.47-6.09)	3.94 (2.66-4.48)	0.77 (0.72-0.80)	3.22 (2.19-3.90)	44.4 (29.3-46.1)	1.0 (0.8-4.1)
9Wait staff/bartenders/cashiers	53	4.42 (3.74-5.17)	3.56 (3.14-4.20)	0.82 (0.79-0.86)	3.94 (3.11-4.59)	13.2 (5.1-39.5)	20(0471)
) 1 Cooks	14	3.38 (2.96-4.24)	2.81 (2.56-3.62)	0.82 (0.79-0.86)	3.08 (2.53-3.80)	25.0 (9.7-36.9)	1.6 (0.8- 4.0)
2 3 ^{p value +}		0.03	0.04	0.04	0.03	0.08	3.0 (0.4-7.1) 1.6 (0.8- 4.0) 0.711 2.0 (0.25-6.9
tours per week exposed to SHS*							
5 6≤26 hrs	39	4.05 (3.58-4.75)	3.44 (2.85-3.91)	0.82 (0.78-0.87)	3.81 (2.89-4.59)	11.3 (3.0-26.0)	2.0 (0.25-6.9
7 8 ^{>27} hrs	36	4.40 (3.45-5.40)	3.64 (2.89-4.32)	0.80 (0.77-0.84)	3.58 (2.78-4.38)	35.8 (11.6-48.1)	3.3 (0.9-7.04
9 p value \pm		0.279	0.457	0.173	0.603	0.0003	0.474
acility 2							
3Smoking/mixed	58	4.24 (3.32-5.26)	3.49 (2.85-4.23)	0.81 (0.77-0.84)	3.58 (2.73-4.44)	21.8 (10.5-44.7)	1.5 (0-5.0)
4 5 ^{Non-smoking} 6	17	4.24 (3.83-4.55)	3.49 (3.28-3.83)	0.84 (0.80-0.88)	3.98 (3.25-4.48)	4.1 (1.5-26.0)	3.3 (0.9-7.04 0.474 1.5 (0-5.0) 2.6 (0.9-7.0)

- 58 59

BMJ Open

11 of 26						
1 .	0.005	0.045	0.07	0.176	0.0012	0.1(1
ulue ±	0.825	0.845	0.06	0.176	0.0012	0.161
	*Variable dichotomized in media	an value; + Kruskal	Wallis test; <u>+</u> Wilcoxo	n Test		
	Consistent with the lite	erature, sex, a	ge and weight	were significantly	y associated with	
		, , ,	0 0			
	pulmonary function par	rameters (Tabl	le 3). In terms	of job function,	the owners and	
			1 1 555	1 020	11 .1 .1	
	managers had FEV ₁ /FV	C values 60%	lower and FEF	$r_{25/75}$ values 830 m	nl lower than the	
	group of wait staff, bart	enders and cas	shiers. The kitch	en workers had 7	00 ml lower FVC	
	group of wait staff, bar	chiefs, and ca	siners. The kitch	ien workers nad 7		
	values, 640 ml lower FI	\mathbf{V}_1 values, and	772 ml lower F	EF _{25/75} than the gi	oup of wait staff,	
				-	-	
	bartenders, and cashiers	. Workers in sr	noking facilities	had 413 ml lowe	r FEF _{25/75} and 3%	
			1.			
	lower FEV ₁ /FVC than w	orkers in non-s	moking venues.			
	Tabla 3 Rivariata assoc	istion of nulm	onary function r	naramatars in non	smakars warkers	
	Table 3. Bivariate assoc	iation of pulm	onary function p	parameters in non	-smokers workers	
	Table 3. Bivariate assoc according to covariables		onary function p	parameters in non	-smokers workers	
			onary function p	parameters in non	-smokers workers	
	according to covariables	of interest.	~			
	according to covariables		FEV ₁ (ml)	FEV ₁ /FVC (ml)) FEF _{25/75} (ml)	1
	according to covariables	of interest.	~			1
Socioden	according to covariables FVC	of interest.	FEV ₁ (ml) β	FEV ₁ /FVC (ml) β) FEF _{25/75} (ml) β	
Sex	according to covariables FVC β (CI95%) nographic variables	of interest.	FEV ₁ (ml) β (CI95%)	FEV ₁ /FVC (ml) β (CI95%)) FEF _{25/75} (ml) β (Cl95%)	
	according to covariables FVC β (CI95%) nographic variables 1,260	of interest.	FEV ₁ (ml) β (CI95%) 0.91	FEV ₁ /FVC (ml) β (CI95%) -0.03) FEF _{25/75} (ml) β (C195%) 0.61	1
Sex Male	according to covariables FVC β (CI95%) nographic variables	of interest.	FEV ₁ (ml) β (CI95%)	FEV ₁ /FVC (ml) β (CI95%)) FEF _{25/75} (ml) β (C195%) 0.61	
Sex	according to covariables FVC β (CI95%) hographic variables 1,260 (0.880 to 1.6)	of interest.	FEV ₁ (ml) β (CI95%) 0.91 0.601 to 1.213)	FEV ₁ /FVC (ml) β (CI95%) -0.03 (-0.064 to -0.0002) FEF _{25/75} (ml) β (C195%) 0.61 3) (0.110 to 1.103)	1
Sex Male	according to covariables FVC β (CI95%) nographic variables 1,260 (0.880 to 1.6 -0.03	of interest.	FEV ₁ (ml) β (CI95%) 0.91 0.601 to 1.213) -0.03	FEV ₁ /FVC (ml) β (CI95%) -0.03 (-0.064 to -0.0002 -0.001) FEF _{25/75} (ml) β (C195%) 0.61 3) (0.110 to 1.103) -0.037	
Sex Male Age	according to covariables FVC β (CI95%) hographic variables 1,260 (0.880 to 1.6)	of interest.	FEV ₁ (ml) β (CI95%) 0.91 0.601 to 1.213)	FEV ₁ /FVC (ml) β (CI95%) -0.03 (-0.064 to -0.0002) FEF _{25/75} (ml) β (C195%) 0.61 3) (0.110 to 1.103) -0.037	1
Sex Male	according to covariables FVC β (CI95%) nographic variables 1,260 (0.880 to 1.6 -0.03 (-0.05 to -0.4)	of interest.	FEV1 (ml) β (C195%) 0.91 0.601 to 1.213) -0.03 -0.04 to -0.02)	FEV ₁ /FVC (ml) β (CI95%) -0.03 (-0.064 to -0.0002 -0.001 (-0.003 to -0.003)	 FEF_{25/75} (ml) β (C195%) 0.61 (0.110 to 1.103) -0.037 (-0.055 to -0.019) 	
Sex Male Age	according to covariables FVC β (CI95%) nographic variables 1,260 (0.880 to 1.6 -0.03 (-0.05 to -0. 0.04	of interest.	FEV ₁ (ml) β (C195%) 0.91 0.601 to 1.213) -0.03 (-0.04 to -0.02) 0.02	FEV ₁ /FVC (ml) β (CI95%) -0.03 (-0.064 to -0.0003 -0.001 (-0.003 to -0.003) -0.001	 FEF_{25/75} (ml) β (C195%) 0.61 (0.110 to 1.103) -0.037 (-0.055 to -0.019) 0.014 	
Sex Male Age Weight	according to covariables FVC β (CI95%) nographic variables 1,260 (0.880 to 1.6 -0.03 (-0.05 to -0.4)	of interest.	FEV1 (ml) β (C195%) 0.91 0.601 to 1.213) -0.03 -0.04 to -0.02)	FEV ₁ /FVC (ml) β (CI95%) -0.03 (-0.064 to -0.0002 -0.001 (-0.003 to -0.003)	 FEF_{25/75} (ml) β (C195%) 0.61 (0.110 to 1.103) -0.037 (-0.055 to -0.019) 0.014 	
Sex Male Age	according to covariables FVC β (CI95%) nographic variables 1,260 (0.880 to 1.6 -0.03 (-0.05 to -0. 0.04	of interest.	FEV ₁ (ml) β (C195%) 0.91 0.601 to 1.213) -0.03 (-0.04 to -0.02) 0.02	FEV ₁ /FVC (ml) β (CI95%) -0.03 (-0.064 to -0.0003 -0.001 (-0.003 to -0.003) -0.001	$\begin{array}{c c} & FEF_{25/75} (ml) \\ & \beta \\ (C195\%) \\ \hline \\ 0.61 \\ (0.110 \text{ to } 1.103) \\ & -0.037 \\ (-0.055 \text{ to } -0.019) \\ & 0.014 \\ 1) & (-0.004 \text{ to } 0.034) \end{array}$	
Sex Male Age Weight	according to covariables FVC β (CI95%) nographic variables 1,260 (0.880 to 1.6 -0.03 (-0.05 to -0.0 0.04 (0.02 to 0.0	of interest.	$\frac{\text{FEV}_{1} \text{ (ml)}}{\beta}$ (CI95%) 0.91 0.601 to 1.213) -0.03 (-0.04 to -0.02) 0.02 (0.01 to 0.04)	FEV ₁ /FVC (ml) β (CI95%) -0.03 (-0.064 to -0.0003 -0.001 (-0.003 to -0.003) -0.001 (-0.002 to -0.0003	 FEF_{25/75} (ml) β (C195%) 0.61 (0.110 to 1.103) -0.037 (-0.055 to -0.019) 0.014 	
Sex Male Age Weight	according to covariables FVC β (C195%) nographic variables 1,260 (0.880 to 1.6 -0.03 (-0.05 to -0.7 0.04 (0.02 to 0.0 0.08	of interest.	$\frac{FEV_1 (ml)}{\beta}$ (CI95%) 0.91 0.601 to 1.213) -0.03 (-0.04 to -0.02) 0.02 (0.01 to 0.04) 0.06	$\frac{\text{FEV}_{1}/\text{FVC (ml)}}{\beta}$ (CI95%) -0.03 (-0.064 to -0.0003 (-0.001 (-0.003 to -0.003) -0.001 (-0.002 to -0.0003 -0.001	$\begin{array}{c} \begin{array}{c} \begin{array}{c} & {\rm FEF}_{25/75} \ ({\rm ml}) \\ & \beta \\ ({\rm C195\%}) \end{array} \\ \end{array} \\ \begin{array}{c} 0.61 \\ 0.110 \ {\rm to} \ 1.103) \\ & -0.037 \\ (-0.055 \ {\rm to} \ -0.019) \\ & 0.014 \\ 1) \end{array} \\ \begin{array}{c} 0.014 \\ (-0.004 \ {\rm to} \ 0.034) \\ & 0.052 \end{array}$	
Sex Male Age Weight Size	according to covariables FVC β (CI95%) nographic variables 1,260 (0.880 to 1.6 -0.03 (-0.05 to -0.1 0.04 (0.02 to 0.0 0.08 (0.07 to 0.1 0.04	of interest.	$\frac{\text{FEV}_{1} \text{ (ml)}}{\beta}$ (C195%) 0.91 0.601 to 1.213) -0.03 (-0.04 to -0.02) 0.02 (0.01 to 0.04) 0.06 0.050 to 0.074) -0.17	$\frac{FEV_{1}/FVC (ml)}{\beta}$ (CI95%) -0.03 (-0.064 to -0.0003 (-0.001 (-0.003 to -0.003) -0.001 (-0.002 to -0.0003 -0.001 (-0.002 to 0.001) -0.054	$\begin{array}{c c} & FEF_{25/75} (ml) \\ & \beta \\ (C195\%) \\ \hline \\ & 0.61 \\ (0.110 \text{ to } 1.103) \\ & -0.037 \\ (-0.055 \text{ to } -0.019) \\ & 0.014 \\ (-0.004 \text{ to } 0.034) \\ & 0.052 \\ (0.029 \text{ to } 0.076) \\ & -0.673 \end{array}$	
Sex Male Age Weight Size Asthma Yes	according to covariables FVC β (C195%) (C195%) nographic variables 1,260 (0.880 to 1.6 -0.03 -0.03 (-0.05 to -0.) 0.04 (0.02 to 0.0) 0.08 (0.07 to 0.1) 0.04 (-0.731 to 0.8)	of interest.	$\frac{\text{FEV}_{1} \text{ (ml)}}{\beta}$ (C195%) 0.91 0.601 to 1.213) -0.03 (-0.04 to -0.02) 0.02 (0.01 to 0.04) 0.06 0.050 to 0.074)	$\frac{\text{FEV}_{1}/\text{FVC (ml)}}{\beta}$ (CI95%) -0.03 (-0.064 to -0.0002 -0.001 (-0.003 to -0.003) -0.001 (-0.002 to -0.0002 -0.001 (-0.002 to 0.001)	$\begin{array}{c c} & FEF_{25/75} (ml) \\ & \beta \\ (C195\%) \\ \hline \\ & 0.61 \\ (0.110 \text{ to } 1.103) \\ & -0.037 \\ (-0.055 \text{ to } -0.019) \\ & 0.014 \\ (-0.004 \text{ to } 0.034) \\ & 0.052 \\ (0.029 \text{ to } 0.076) \\ & -0.673 \end{array}$	
Sex Male Age Weight Size Asthma Yes	according to covariables FVC β (CI95%) nographic variables 1,260 (0.880 to 1.6 -0.03 (-0.05 to -0.1 0.04 (0.02 to 0.0 0.08 (0.07 to 0.1 0.04 (-0.731 to 0.8 onal exposure variables	of interest.	$\frac{\text{FEV}_{1} \text{ (ml)}}{\beta}$ (C195%) 0.91 0.601 to 1.213) -0.03 (-0.04 to -0.02) 0.02 (0.01 to 0.04) 0.06 0.050 to 0.074) -0.17	$\frac{FEV_{1}/FVC (ml)}{\beta}$ (CI95%) -0.03 (-0.064 to -0.0003 (-0.001 (-0.003 to -0.003) -0.001 (-0.002 to -0.0003 -0.001 (-0.002 to 0.001) -0.054	$\begin{array}{c c} & FEF_{25/75} (ml) \\ & \beta \\ (C195\%) \\ \hline \\ & 0.61 \\ (0.110 \text{ to } 1.103) \\ & -0.037 \\ (-0.055 \text{ to } -0.019) \\ & 0.014 \\ (-0.004 \text{ to } 0.034) \\ & 0.052 \\ (0.029 \text{ to } 0.076) \\ & -0.673 \end{array}$	
Sex Male Age Weight Size Asthma Yes	according to covariables FVC β (C195%) (C195%) nographic variables 1,260 (0.880 to 1.6 -0.03 -0.03 (-0.05 to -0.) 0.04 (0.02 to 0.0) 0.08 (0.07 to 0.1) 0.04 (-0.731 to 0.8)	of interest.	$\frac{\text{FEV}_{1} \text{ (ml)}}{\beta}$ (C195%) 0.91 0.601 to 1.213) -0.03 (-0.04 to -0.02) 0.02 (0.01 to 0.04) 0.06 0.050 to 0.074) -0.17	$\frac{FEV_{1}/FVC (ml)}{\beta}$ (CI95%) -0.03 (-0.064 to -0.0003 (-0.001 (-0.003 to -0.003) -0.001 (-0.002 to -0.0003 -0.001 (-0.002 to 0.001) -0.054	$\begin{array}{c c} & FEF_{25/75} (ml) \\ & \beta \\ (C195\%) \\ \hline \\ & 0.61 \\ (0.110 \text{ to } 1.103) \\ & -0.037 \\ (-0.055 \text{ to } -0.019) \\ & 0.014 \\ (-0.004 \text{ to } 0.034) \\ & 0.052 \\ (0.029 \text{ to } 0.076) \\ & -0.673 \end{array}$	

	FVC (ml)	FEV_1 (ml)	FEV ₁ /FVC (ml)	FEF _{25/75} (ml)
	β	β	β	β
	(CI95%)	(CI95%)	(CI95%)	(CI95%)
Sociodemographic variable	les			
Sex				
Male	1,260	0.91	-0.03	0.61
	(0.880 to 1.650)	(0.601 to 1.213)	(-0.064 to -0.0003)	(0.110 to 1.103)
Age				
	-0.03	-0.03	-0.001	-0.037
	(-0.05 to -0.02)	(-0.04 to -0.02)	(-0.003 to -0.003)	(-0.055 to -0.019)
Weight				
	0.04	0.02	-0.001	0.014
	(0.02 to 0.05)	(0.01 to 0.04)	(-0.002 to -0.0001)	(-0.004 to 0.034)
Size				
	0.08	0.06	-0.001	0.052
	(0.07 to 0.10)	(0.050 to 0.074)	(-0.002 to 0.001)	(0.029 to 0.076)
Asthma				
Yes	0.04	-0.17	-0.054	-0.673
	(-0.731 to 0.802)	(-0.750 to 0.422)	(-0.100 to -0.010)	(-1.470 to 0.122)
Occupational exposure va	riables			
Job function at the facility				
				11
				11

BMJ Open: first published as 10.1136/bmjopen-2017-017811 on 6 October 2017. Downloaded from http://bmjopen.bmj.com/ on April 19, 2024 by guest. Protected by copyright

Wait staff/bartenders/cashier	s <i>Ref.</i>	Ref.	Ref.	Ref.
Owners/managers	0.37	0.003	-0.06	-0.828
(•	0.370 to 1.110)	(-0.570 to 0.570)	(-0.113 to -0.021)	(-1.613 to -0.047)
Cooks	-0.7	-0.64	-0.02	-0.772
	(-1.290 to -0.120)	(-1.090 to -0.190)	(-0.061 to 0.022)	(-1.391 to -0.151)
Hours per week exposed to SH	S			
	0.01	0.01	-0.0004	0.002
	(0.002 to 0.020)	(-0.0005 to 0.014)	(-0.001 to 0.0002)	(-0.008 to 0.011)
Facility				
Non-smoking	Ref.	Ref.	Ref.	Ref.
Smoking/mixed	0.1	-0.05	-0.03	-0.413
	(-0.460 to 0.672)	(-0.486 to 0.381)	(-0.071 to 0.003)	(-1.003 to 0.177)

Association between pulmonary function and SHS exposure

The crude model revealed that the association between pulmonary function and urine cotinine concentration was not statistically significant (Table 4). The multivariate analysis was based on a parsimonious model that included the covariate "job function", as this variable was related to pulmonary function and urine cotinine concentration with a p-value<0.10, as well as the variables sex, age, weight, height, and asthma status, all of which are recognized as variables that affect pulmonary function according to SEPAR ^{29, 32}. The adjusted model did not demonstrate a significant association between urine cotinine concentration and decreased pulmonary function. Conversely, the number of years of SHS exposure in workplace showed an inverse and significant associated with years of SHS exposure was associated with a 200 ml decrease in FEV₁ (95% CI -0.042 to -0.001). The other pulmonary function variables were also inversely associated with years of SHS exposure in workplace, although the association in these cases did not reach significance. The adjusted model showed an inverse and in some cases statistically significant

association between the number of years of SHS exposure and pulmonary function parameters, specifically in FEF $_{25/75}$ (β = -0.006; 95% CI -0.010 to -0.0004).

Table 4. Crude and adjusted association between pulmonary function parameters andSHS exposure of non-smoking workers of bars and restaurants.

	FVC (ml)		FVC (ml) FEV ₁ (ml)		FEV ₁ /FVC (m	ıl)	FEF25/75 (ml)	
	β (CI95%)	R ²	β (CI95%)	R ²	β (CI95%)	R ²	β (CI95%)	R ²
Urine cotinine		2						
Crude model	0.002	0.002	0.002	0.003	0.0002	0.002	0.002	0.002
	(-0.010 to 0.010)		(-0.010 to 0.010)		(-0.001 to 0.001)		(-0.010 to 0.010)	
Adjusted model	-0.0002	0.781	0.001	0.795	0.0004	0.33	0.005	0.672
	(-0.007 to 0.006)*		(-0.003 to 0.006)*		(-0.0003 to 0.001)+		(-0.006 to 0.015)+	
Number of	f years exposed to SHS	at work						
Crude model	-0.025	0.0462	-0.022	0.061	-0.0008	0.013	-0.022	0.032
	(-0.051 to 0.002)		(-0.042 to -0.001)		(-0.002 to 0.0008)		(-0,050 to 0,006)	
Adjusted model	-0.013	0.79	-0.01	0.802	0.0006	0.324	-0.006	0.964
	(-0.030 to 0.0025)*		(-0.022 to 0.002)*		(-0.001 to 0.002)+		(-0,010 to -0,0004)+	

*Adjusted by sex, age, weight, size and job function at the facility; + Adjusted by sex, age, size, asthma status and job function at the facility

Discussion

This study is the first in Chile to evaluate occupational SHS exposure and its association with specific pulmonary function parameters. We did not find an inverse association between pulmonary function parameters and urine cotinine concentration, but when we considered number of years exposed to SHS in workplace, we found an inverse association with FVC (ml), FEV₁ (ml), FEV₁/FVC (ml) and FEF _{25/75} being significant only for the last parameter. Similar findings were described by other researchers who reported a reduction in FVC and FEF_{25/75}^{20, 33}, in FVC ¹⁵, in FVC and FEV1¹⁶ in subjects exposed to environmental tobacco smoke. In terms of job function, kitchen workers showed lower pulmonary function values than the group of wait staff, bartenders, and cashiers as compared to the owners and managers. One possible explanation for these findings is that the SHS exposure had an additive effect with exposure to other pollutants emitted in the kitchen. In the literature has been reported that workers in kitchens with gas stoves show lower pulmonary function parameters than those in kitchens with electric stoves, due to greater exposure to toxic substances in the air after cooking with gas ³⁴. In our study, it was not possible to analyze differences according this variable because 100% of the establishments used gas stoves.

As noted above, we did not find a significant association between pulmonary function parameters and urine cotinine concentration. A possible explanation for these results is that, urine cotinine levels reflect recent exposure to tobacco smoke ^{21, 22, 31} while chronic exposure to SHS is likely implicated in a decline in pulmonary function parameters. In fact, in Table 4 we can see that the proportion of the variance (R^2) explained by *number of years of SHS exposure in workplace* is greater than that explained by the current *urine cotinine*

concentration, suggesting that this variable (*number of years of SHS exposure*) may be more apropriate when we are studying chronic effects. Other studies that have addressed this topic have produced varying results ^{15, 16, 17, 20, 21, 22, 31, 35} reported a significant inverse association between SHS exposure (evaluated through self-report) and FVC and FEV₁. As in our study, Chen et al. did not find a significant association when serum cotinine was assess as exposure variable, but did when exposure to SHS was measured through self-report ¹⁶.

Our results are not as strong as those described in other studies ^{12, 13, 14, 20, 33}. It should be noted that our sample included mainly young workers being reasonable to infer that the sample not accumulated sufficient years of SHS exposure to register significant changes in pulmonary function. Also the median time worked at the location was only about 1 year. About 25% of the sample had worked at the given facility for less than 3 months, and 75% of the sample had worked at the location for fewer than 2 years. This condition of high turnover rate, along with the relative youth of the workers contributes to assume that the sample not accumulated enough years of SHS exposure to register significant changes in pulmonary function. A second limitation was that although all participants were nonsmokers, those who worked in non-smoking venues reported be exposed to SHS at least 4 hours a week. Also in this group the median urine concentration was 4.1 ng/ml. The lack of a true control group could have lead to underestimating the effect of SHS exposure. Another potential limitation was the timing of the spirometry measurements. The literature reports that pulmonary function varies throughout the day according to circadian rhythm, decreasing from a high point in the early morning until about noon and then rising again to peak between about 4 and 5 in the afternoon. These daily fluctuations may have

BMJ Open: first published as 10.1136/bmjopen-2017-017811 on 6 October 2017. Downloaded from http://bmjopen.bmj.com/ on April 19, 2024 by guest. Protected by copyright

affected the results, as the lung function measurements were performed at various times of day, according to the availability and shifts of the workers and establishments. Finally, our small sample size along with the weak correlation between exposure to SHS and pulmonary function prevent us to have enough power to demonstrate a strongest association as shown in other studies.

Notwithstanding the above, our study shows that exposure to SHS among non-smoking employees working in venues where smoking is allowed appear to be substantially higher than those found in employees working in venues where smoking is not allow. The median urine cotinine in non-smoking employees working in a venue were smoking is allowed was 40.0 ng/ml, in a mixed venue was 13.5 ng/ml and where smoking was not allow was 4.1 ng/ml. Given that SHS is a proven carcinogen in humans to which non-smoking workers of this type of venues are exposed involuntarily, a total smoking ban would provide a major protection to employees working in such venues.

Conclusion

The years of exposure to SHS in workplace as proxy of chronic exposure were inverse and significantly associated with the $\text{FEF}_{25/75}$, and inverse but not significant with FVC and FEV_1 . These findings suggest that cumulative exposure to SHS at work may contribute to deterioration of pulmonary function in non-smoking employees.

Acknowledgments

The authors would like to thank to employees, managers and venue owners who agreed to participate in this study. Also to the Department of Research of the Universidad de Los Andes-Chile for the support given to translate this article.

Competing interest

The authors have no conflict of interest to declare.

Funding

This study was supported by National Fund for Research and Development in Health FONIS, CONICYT – MINSAL, Research Grant # SA09I062 and by International Training and Research in Environmental and Occupational Health (ITREOH), Fogarty International Center, NIH Research Grant #D43TW005746-02.

References

- Aceituno Paulina, Iglesias Verónica, Erazo Marcia, Droppelmann Andrea, Orellana Cecilia, Navas-Acién Ana. 2010. The work environment as a source of exposure to secondhand smoke: a study in workers of bars and restaurants of Santiago, Chile. *Rev Med Chile* 138:1517-1523.
- Alwan A. World Health Organization. 2009. WHO Report on the Global Tobacco Epidemic. Implementing smoke-free environments; [Cited 2016 Jun 24]. Available from: <u>http://who.int/tobacco/mpower/2009/gtcr_download/en/index.html</u>
- Bello Sergio, Michalland Susana, Soto Marina, Contreras Carla, Salinas Judith. 2005. Effects in passive smokers of environmental tobacco smoke exposure. *Rev Chil Enf Respir* 21:179-192.
- Chan-Yeung Moira, Dimich-Ward Helen. 2003. Respiratory health effects of exposure to environmental tobacco smoke. *Respirology* 8(2):131-139.
- 5. Collishaw Neil E, Kirkbride John, Wigle Donald. 1984. Tobacco smoke in the workplace: an occupational health hazard. *Can Med Assoc J* 131(10):1191-1204.

- 6. EPA. Proposed identification of environmental tobacco smoke as a Toxic Air Contaminant. Tobacco Control. Surveys and Program Evaluations from Outside UCSF Paper CALEPA2005 2005 [cited 2017 July 18]; Available from: https://oehha.ca.gov/media/downloads/air/report/app32005.pdf
- Department of Health and Human Services USA. 2014. The consequences of smoking on health. 50 years of progress. Report of the US Department of Health and Human Services USA. Executive Summary.
- OMS-OPS. 2016. Report on tobacco control in the Region of the Americas. 10 years of the Framework Convention of the World Health Organization for tobacco control. Washington D.C.
- Allwright Shane, Paul Gillian, Greiner Birgit, Mullally Bernie J, Pursell Lisa, Kelly Alan et al. Legislation for smoke-free workplaces and health of bar workers in Ireland: before and after study. *BMJ* 2006 332(7534):151.
- Coultas David. 1998. Health effects of passive smoking. Passive smoking and risk of adult asthma and COPD: an update. *Thorax* 53(5):381-387.
- 11. De Vito Eduardo, Rojas Ramón. 2005. Environmental tobacco smoke. *Medicina (B. Aires)* 65(6):545-549.
- Jaakkola Maritta, Jaakkola Jouni, Becklake Margaret, Ernst Pierre. 1995. Passive smoking and evolution of lung function in young adults. An 8-year longitudinal study. J *Clin Epidemiol* 48(3):317-327.
- Jayet Pierre-Yves, Schindler Christian, Schwartz Joel, Kunzli Nino, Zellweger Pierre,
 Ackermann-Liebrich Ursula, Leuenberger Phillippe. 2005. Passive smoking exposure

BMJ Open

among adults and the dynamics of respiratory symptoms in a prospective multicenter cohort study. *Scand J Work Environ Health* 31(6):465-473.

- 14. Rizzi Maurizio, Sergi Margherita, Andreoli Arnaldo, Pecis Marica, Bruschi Claudio, Fanfulla Francesco. 2004. Environmental tobacco smoke may induce early lung damage in healthy male adolescents. *Chest* 125(4):1387-1393.
- 15. Alipour Shahryar, Deschamps Frédéric, Lesage FranÇois-Xavier. 2005. Effects of Environmental Tobacco Smoke on Respiratory Symptoms and Pulmonary Function. *Inhal Toxicol* 18(8):569-573.
- 16. Chen Ruoling, Tunstall-Pedoe H, Tavendale R. 2001. Environmental tobacco smoke and lung function in employees who never smoked: the Scottish MONICA study. *Occup Environ Med* 58(9):563-568.
- 17. Fidan F, Cimrin AH, Ergor G, Sevinc C. 2004. Airway disease risk from environmental tobacco smoke among coffeehouse workers in Turkey. *Tob Control* 13(2):161-6.
- 18. Janson Christer, Chinn Susan, Jarvis Deborah, Zock Jan-Paul, Torén Kjell, Burney Peter. 2001. Effects of passive smoking on respiratory symptoms, bronchial responsiveness, lung function, and total serum IgE in the European Community Respiratory Health survey: a cross sectional study. *Lancet* 358(2):103-109.
- 19. Eisner Mark D. 2002. Environmental tobacco smoke exposure and pulmonary function among adults in NHANES III: impact on the general population and adults with current asthma. *Environ Health Perspect* 110(8):765-70.
- 20. Kunzli N, Schwartz J, Stutz EZ, Ackermann-Liebrich U, Leuenberger P. 2000. Association of environmental tobacco smoke at work and forced expiratory lung function among never smoking asthmatics and non-asthmatics. The SAPALDIA-Team.

 Swiss Study on Air Pollution and Lung Disease in Adults. *Soz Praventivmed* 45(5):208-17.

- 21. Benowitz Neal L. 1999. Biomarkers of environmental tobacco smoke exposure. *Environ Health Perspect* 107(2):349-55.
- 22. Tutka Piotr, Mosiewicz Jerzy, Wielosz Marian. 2005. Pharmacokinetics and metabolism of nicotine. *Pharmacol Rep* 57(2):143-53.
- 23. Centers for Disease Control and Prevention. 2017. National Report of Human Exposure to Environmental Chemicals; [Cited 2017 March 15]. Available from: <u>https://www.cdc.gov/exposurereport/</u>
- 24. Al-Delaimy WK, Crane J, Woodward A. 2000. Questionnaire and hair measurement of exposure to tobacco smoke. *J Expo Anal Environ Epidemiol* 10:378-384.
- 25. Al-Delaimy WK. 2002. Hair as a biomarker for exposure to tobacco smoke. *Tob Control* 11:176-182.
- 26. Iglesias Verónica, Erazo Marcia, Droppelmann Andrea, Steenland Kyle, Aceituno Paulina, Orellana Cecilia, Acuña Marisol, Peruga Armando, Breysse Patrick N, Navas-Acien Ana. 2014. Occupational secondhand smoke is the main determinant of hair nicotine concentrations in bar and restaurant workers. *Environ Res* 132:206–211.
- 27. Salud OMS. 2003. "Convenio Marco de la OMS para el control del tabaco"; [Cited 2016 Jun 24]. Available from: <u>http://www.who.int/fctc/text_download/es/</u>.
- 28. Muñoz Claudio, Droppelmann Andrea, Erazo Marcia, Aceituno Paulina, Orellana Cecilia, Parro Javiera, Mesias Stephanie, Marchetti Nella, Navas-Acien Ana, Iglesias Verónica. 2016. Occupational exposure to polycyclic aromatic hydrocarbons: A cross-

BMJ Open

sectional study in bars and restaurants in Santiago, Chile. Am J Ind Med. Version of record online: 28 Jun 2016.

- 29. Burgos Felipe, Casan Pere, Del Campo Félix, Gáldiz Juan, Giner Jordi, González-Mangado Nicolás, Ortega Francisco, Puente Luis, García Francisco, Calle Myriam. SEPAR Regulation: Forced Spirometry. 2013; [Cited 2016 Jun 24]. Available from: <u>http://www.ics.gencat.cat/3clics/guies/184/img/--guiasepar20131.pdf</u>
- 30. Gutiérrez C. Mónica, Beroíza Teresa, Barzone Gisella, Caviedes Iván, Céspedes Iván, Céspedes Juan, Gutiérrez N. Mónica, Moreno Rodrigo, Oyarzún Manuel, Palacios Sylvia, Schonffeldt Patricia. 2007. Spirometry: Procedures Manual. Chilean Society of Respiratory Diseases, 2006. *Rev Chil Enf Respir* 23:31-42.
- 31. Vine Marilyn, Hulka Barbara, Margolin Barry, Truong Young, Hu Ping-chuan, Schramm Margaret, Griffith Jack, McCann Margaret, Everson Richard. 1993. Cotinine Concentrations in Semen, Urine, and Blood of Smokers and Nonsmokers. *Am J Public Health* 83(9):1335-1338.
- 32. Tong Shilu, Lu Ying. 2001. Identification of confounders in the assessment of the relationship between lead exposure and child development. *Ann Epidemiol* 11(1): 38-45.
- Fahim Aymn Ekram, El-Prince Mahmoud. Passive smoking, pulmonary function and bronchial hyper-responsiveness among indoor sanitary workers. *Industrial health* 2012 59: 516-520.
- 34. Wong Tze Wai, Wong Andromeda H, Lee Frank S, Qiu Hong. 2011. Respiratory health and lung function in Chinese restaurant kitchen workers. *Occup Environ Med* 68(10):746-752.

35. Skogstad M, Kjaerheim K, Fladseth G, GjØlstad M, Daae HL, Olsen R, Molander P, Ellingsen DG. 2006. Cross shift changes in lung function among bar and restaurant workers before and after implementation of a smoking ban. *Occup Environ Med* 63:482-487.

Contributorship statement

 Parro Javiera. Substantial contributions to the conception and design of the work on pulmonary function parameters; acquisition, analysis and interpretation of data, drafting the work, and final approval of the version to be published;

Aceituno Paulina. Substantial contributions to the conception and design of the work, revising it critically for important intellectual content, final approval of the version to be published.

Droppelman Andrea. Substantial contributions to the conception, design of the work and interpretation of exposure data, final approval of the version to be published.

Mesías Sthepanie. Substantial contributions to the acquisition and analysis of exposure data, final approval of the version to be published.

Muñoz Claudio. Substantial contributions to the acquisition, analysis and interpretation of data, final approval of the version to be published.

Marchetti Nella. Substantial contributions to the conception of the work and interpretation of data, final approval of the version to be published.

Iglesias Verónica. Substantial contributions to the conception and design of the work, analysis and interpretation of data for the work; drafting the work, final approval of the

version to be published, agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

BMJ Open: first published as 10.1136/bmjopen-2017-017811 on 6 October 2017. Downloaded from http://bmjopen.bmj.com/ on April 19, 2024 by guest. Protected by copyright

STROBE Statement-checklist of items that should be included in reports of observational studies

		BMJ Open	Page
STROBE Statement	-checl	klist of items that should be included in reports of observational studies	
	Item No	Recommendation	
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract page 1 line 1-2	
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found page 2 line 1-22	_
Introduction		puge 2 mile i 22	
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported page 3-5	_
Objectives	3	State specific objectives, including any prespecified hypotheses page 5 line 4	
Methods			_
Study design	4	Present key elements of study design early in the paper page 5 line 8	_
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection page 5 line 13-23	_
Participants	6	(a) Cohort study—Give the eligibility criteria, and the sources and methods of	_
-		selection of participants. Describe methods of follow-up	
		Case-control study—Give the eligibility criteria, and the sources and methods of	
		case ascertainment and control selection. Give the rationale for the choice of cases	
		and controls	
		<i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants page 5 line 13-23	
		(b) Cohort study—For matched studies, give matching criteria and number of	
		exposed and unexposed	
		<i>Case-control study</i> —For matched studies, give matching criteria and the number of	
		controls per case	
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect	
Data sources/	8*	modifiers. Give diagnostic criteria, if applicable page 6 line 4-23, page 7 line 1-8 For each variable of interest, give sources of data and details of methods of	_
	0 °	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is	
measurement		more than one group page 6 line 4-23, page 7 line 1-8	
Bias	9	Describe any efforts to address potential sources of bias	_
Study size	10	Explain how the study size was arrived at NO	_
Quantitative variables	10	Explain how due study size was arrived at two Explain how quantitative variables were handled in the analyses. If applicable,	_
X autorium (Variautico)	11	describe which groupings were chosen and why page 7 line 19-22, page 8 line 1-8.	
Statistical methods	12	(<i>a</i>) Describe all statistical methods, including those used to control for confounding	_
	12	page 7 line 10-20	_
		(b) Describe any methods used to examine subgroups and interactions page 7 line 10-20	_
		(c) Explain how missing data were addressed not apply	_
		(d) Cohort study—If applicable, explain how loss to follow-up was addressed	
		<i>Case-control study</i> —If applicable, explain how matching of cases and controls was addressed	
		Cross-sectional study-If applicable, describe analytical methods taking account of	

1 2	sampling strategy page 7 line 10-20
2 3	(<u>e</u>) Describe any sensitivity analyses NO
4 5	Continued on next page
5 6 7	
7 8 9	
9 10	
11	
12 13	
14 15	
16 17	
18	
19 20	
21 22	
23 24	
25	
26 27	
28 29	
30 31	
32	
33 34	
35 36	
37 38	
39	
40 41	
42 43	
44 45	
46	
47 48	
49 50	
51 52	
53	
54 55	
56 57	
58 59	
59 60	
	For peer review only - http://bmjoper?bmj.com/site/about/guidelines.xhtml

י ר
2
3
4
5
6
2 3 4 5 6 7 8 9 10
8
9
10
11
12
13
1/
15
12 13 14 15 16 17 18
10
17
18
19
13 20 21 22 23 24 25 26 27 28 30 31 32 33 34 35 36 37 38 39
21
22
23
24
25
26
27
28
20
20
20
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
43 46
40 47
48
49
50
51
51 52 53
53
54
55
56
57
58
59
60
50

Results		
Participants	13*	 (a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed page 8 line 1-8 (b) Give reasons for non-participation at each stage page 8 line 1-8 (c) Consider use of a flow diagram NO
Descriptive data	14*	 (a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders page 8 table 1
		 (b) Indicate number of participants with missing data for each variable of interest not apply (c) <i>Cohort study</i>—Summarise follow-up time (eg, average and total amount)
Outcome data	15*	Cohort study—Report numbers of outcome events or summary measures over time Case-control study—Report numbers in each exposure category, or summary measures of exposure
Main results	16	<i>Cross-sectional study</i> —Report numbers of outcome events or summary measures NO (<i>a</i>) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included page 13 Table 4
		 (b) Report category boundaries when continuous variables were categorized page 10 Table 2 (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period NO
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses NO
Discussion		
Key results	18	Summarise key results with reference to study objectives page 14 line 2-17
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias page 15 line 8-23 page 16 line 1-5
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence page 16 line 15-18
Generalisability	21	Discuss the generalisability (external validity) of the study results NO
Other information	on	
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based page 17 line 2

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at www.strobe-statement.org.

BMJ Open

Secondhand tobacco smoke exposure and pulmonary function: a cross-sectional study among non-smoking employees of bar and restaurants in Santiago, Chile

Journal:	BMJ Open
Manuscript ID	bmjopen-2017-017811.R2
Article Type:	Research
Date Submitted by the Author:	24-Aug-2017
Complete List of Authors:	Parro, Javiera; Universidad de Los Andes, Facultad de Enfermería Aceituno, Paulina; Universidad de Chile, Facultad de Medicina, Escuela de Salud Pública Droppelmann, Andrea; Instituto de Salud Pública, Laboratorio de Salud Ocupacional Mesías, Sthepanie; Universidad de Chile, Facultad de Medicina, Escuela de Salud Pública muñoz, claudio; Universidad de La Frontera, Facultad de Medicina Marchetti, Nella; Universidad de Chile, Facultad de Medicina, Escuela de Salud Pública Iglesias, Verónica; Universidad de Chile, Facultad de Medicina, Escuela de Salud Pública
Primary Subject Heading :	Occupational and environmental medicine
Secondary Subject Heading:	Smoking and tobacco
Keywords:	RESPIRATORY MEDICINE (see Thoracic Medicine), PUBLIC HEALTH, OCCUPATIONAL & INDUSTRIAL MEDICINE

SCHOLARONE[™] Manuscripts

BMJ Open

2	
3	
1	
4	
5	
6	
7	
8	
à	
10	
10	
11	
12	
13	
14	
15	
10	
16	
17	
18	
19	
20	
21	
<u>~1</u>	
22	
$3 \\ 4 \\ 5 \\ 6 \\ 7 \\ 8 \\ 9 \\ 10 \\ 11 \\ 23 \\ 11 \\ 12 \\ 12 \\ 23 \\ 24 \\ 5 \\ 6 \\ 7 \\ 8 \\ 9 \\ 10 \\ 11 \\ 21 \\ 22 \\ 23 \\ 24 \\ 5 \\ 27 \\ 28 \\ 20 \\ 31 \\ 22 \\ 30 \\ 32 \\ 20 \\ 31 \\ 30 \\ 31 \\ 30 \\ 31 \\ 30 \\ 31 \\ 30 \\ 31 \\ 30 \\ 31 \\ 30 \\ 31 \\ 30 \\ 31 \\ 30 \\ 31 \\ 30 \\ 31 \\ 30 \\ 31 \\ 30 \\ 31 \\ 30 \\ 31 \\ 30 \\ 31 \\ 30 \\ 31 \\ 30 \\ 30$	
24	
25	
26	
27	
21	
28	
29	
29 30 31 32 33 34 35 36 37 38 39	
31	
32	
33	
24	
34	
35	
36	
37	
38	
39	
40	
40	
41	
42	
43	
44	
45	
46	
47	
48	
49	
50	
51	
52	
53	
54	
55	
56	
57	
58	
59	
60	
00	

1	Secondhand tobacco smoke exposure and pulmonary function: a cross-sectional
2	study among non-smoking employees of bar and restaurants in Santiago, Chile
3	
4	Javiera Parro. Escuela de Enfermería, Universidad de Los Andes. Santiago, Chile.
5	Paulina Aceituno. Escuela de Salud Pública, Facultad de Medicina, Universidad de Chile.
6	Santiago, Chile.
7	Andrea Droppelmann. Laboratorio de Salud Ocupacional, Instituto de Salud Pública.
8	Santiago, Chile.
9	Sthepanie Mesías. Escuela de Salud Pública, Facultad de Medicina, Universidad de Chile.
10	Santiago, Chile.
11	Claudio Muñoz. Facultad de Medicina, Universidad de La Frontera. Temuco, Chile.
12	Nella Marchetti. Escuela de Salud Pública, Facultad de Medicina, Universidad de Chile.
13	Santiago, Chile.
14	Verónica Iglesias, Escuela de Salud Pública, Facultad de Medicina, Universidad de Chile.
15	Santiago, Chile.
16	Corresponding author:
17	Verónica Iglesias Alamos.
18	Postal address: Independencia 939, Independencia, Santiago Chile, 8380453.
19	Email: <u>viglesia@med.uchile.cl</u> .
20	Telephone number: 56-229786397.
21	Word count: 2.673
22	
23	
	1

BMJ Open: first published as 10.1136/bmjopen-2017-017811 on 6 October 2017. Downloaded from http://bmjopen.bmj.com/ on April 19, 2024 by guest. Protected by copyright

1 Abstract

Introduction. The workplace remains a significant source of secondhand smoke (SHS) exposure. This pollutant is known to be associated with respiratory and cardiovascular problems, but its effects on specific pulmonary function parameters remain largely unexplored. The objectives of this study were to measure SHS exposure among nonsmoking employees of bar and restaurants in Santiago, Chile and to evaluate the effects of such exposure on pulmonary function.

Methods. Cross-sectional design. The study sample included non-smoking workers from
57 restaurants and bars in Santiago, Chile. The outcome variable was pulmonary function
and the exposure variables were urine cotinine concentration, a biomarker for current SHS
exposure, and years of SHS exposure in the workplace as proxy of chronic exposure.
Personal and occupational variables were also recorded. Data analysis was performed using
linear regression models adjusted by confounders.

Results. The median age of the workers was 35 years and the median employment duration 15 at the analysed venues was 1 year. Workers in smoking facilities reported greater SHS 16 exposure (36 hours per week) than workers in smoke-free locations (4 hours per week). 17 Urine cotinine levels were inversely correlated with forced vital capacity (FVC), but the 18 finding was not statistically significant (β =-0.0002; 95% CI: -0.007 to 0.006). Years of 19 exposure to SHS showed to be significantly associated with FEF25 / 75 (β = -0.006; 95% 20 CI: -0.010 to -0.0004).

21 Conclusion. These findings suggest that cumulative exposure to SHS at work may22 contribute to deterioration of pulmonary function in non-smoking employees.

BMJ Open

Keywords: Secondhand smoke exposure, chronic exposure, pulmonary function, urine cotinine, workers. Strengths and limitations of this study - The effects of occupational SHS exposure on specific pulmonary function parameters has been scarcely explored. - This study is the first in Chile to evaluate occupational SHS exposure and its association with specific pulmonary function parameters. - The use of the variable "number of years exposed to SHS at workplace" was appropriate to studied chronic SHS exposure. - Our sample included mainly young workers being reasonable to infer that the sample not accumulated sufficient years of SHS exposure to register greater changes in pulmonary function. - Daily fluctuations of the timing of the spirometry measurements may have affected the results, since these were performed at various times of day, according to the availability and shifts of the workers and establishments.

4 Introduction

The secondhand smoke (SHS) is the smoke that remains in the air after someone has consumed tobacco, including the smoke coming from the burning end of the cigarette (sidestream smoke) and the smoke exhaled by the smoker (mainstream smoke)¹⁻⁵. Side-stream smoke contains higher concentration of harmful substances than main stream as it contains a greater amount of toxic gases and smaller particles that reach greater depth in the lungs

when inhaled⁶. SHS is a common indoor pollutant in restaurants and bars that poses a serious health risk for non-smokers as it contains over 50 substances known to be carcinogenic in humans^{7, 8}. There is no known safe exposure level^{1, 4}. Some of the highest and most sustained occupational exposure to SHS occur in bar staff, with non-smoking areas providing only limited protection⁹.

SHS exposure can lead to the same health problems associated with active smoking^{1, 7, 8}. with risk levels increasing as a function of hours of exposure¹⁰⁻¹⁴. Common scenarios associated with chronic SHS exposure include living with a spouse or parent who smokes and working in a location where smoking is allowed ^{3, 5}. Previous studies have not been consistent in showing a decline in specific pulmonary function parameters in people affected by SHS exposure at work or at home^{9, 15-20}. This lack of evidence may be attributable to the methods use to measure SHS exposure, which range from self-report to measurement of exposure biomarkers¹⁵⁻¹⁹.

One of the most common ways of measuring SHS exposure is measuring concentration of cotinine, the principle metabolite of nicotine. Cotinine can be measured in the blood or urine and shows high sensitivity and specificity for acute SHS exposure (over the past 3–4 days), although some authors have also used it to evaluate longer-term exposure²¹⁻²³. Chronic exposure to SHS has been measured through questionnaire and by hair nicotine concentration^{24, 25}.

In 2010, the time at which this study was performed, Chilean law prohibited tobacco smoking in public areas and workplaces. However, there were exceptions for "hospitality" venues, such as casinos, bars, pubs, restaurants, and cafés. Bars, pubs, and restaurants with areas smaller than100 m² could choose to allow smoking indoors or not, while facilities

BMJ Open

with an area larger than 100 m² were required to offer separate sections for smokers and
nonsmokers. Therefore, "hospitality" workers were unprotected from SHS exposure,
becoming the workplace, in many cases, the main source of SHS exposure^{26, 27}.

The objectives of this study were to measure SHS exposure among non-smoking workers in
restaurants and bars in Santiago, Chile and to evaluate the effects of such exposure on
pulmonary function.

7 Methods

8 This cross-sectional study was performed as part of a larger project, "Impact of involuntary
9 exposure to tobacco smoke on respiratory health: study of pub and restaurant workers",
10 carried out in Santiago, Chile between September 2010 and January 2011. This study was
11 approved by the University of Chile School of Medicine's Ethics Committee.

Population and sample

The selection process for participating facilities has been previously described in detail²⁸. In brief, the sampling framework included the 5 municipalities with the largest numbers of facilities, according to data provided by the National Institute of Statistics (Spanish acronym INE, for Instituto Nacional de Estadísticas). Study staff visited 690 locations and used a brief survey to record the venue's name, address, type of facility (bar/pub, restaurant, or other), smoking status (smoking allowed in all areas; designated smoking/non smoking areas; or smoke-free), and number of non-smoking workers. Of the 690 facilities, 207 met inclusion criteria (be a bar-pub or restaurant and have non-smoking workers). Of them, 108 were visited or contacted by telephone to invite the owner or manager to participate in the study. In 63 establishments they agreed to participate (58%). For logistical reasons, only 59 of the facilities were included²⁸. Smoking and non-smoking workers in these facilities were

BMJ Open: first published as 10.1136/bmjopen-2017-017811 on 6 October 2017. Downloaded from http://bmjopen.bmj.com/ on April 19, 2024 by guest. Protected by copyright

invited to participate in the main study. Only those who had not smoked in the last year were included in the current study. Workers were excluded if they did not provide a urine sample (n=5) or had a contraindication for spirometry $(n=1)^{29, 30}$.

Outcome variables

Pulmonary function parameters: Certified personnel used an Easy One Diagnostic® to measure forced vital capacity (FVC) and forced expiratory volume in 1s (FEV₁), and then calculated the FEV₁ to FVC ratio (FEV₁/FVC) and forced expiratory flow as 25%–75% of FVC (FEF₂₅₋₇₅). Spirometry measurements were performed during working hours. In compliance with international norms on collecting and interpreting spirometry data, age, sex, weight, height, and race of each participant were also recorded^{29, 30}. A maximum of 8 spirometry trials were performed. The criteria for including a participant's spirometry data in the analysis was achieving at least 3 acceptable and 2 reproducible trials, as described in the norms published by Spanish Society of Pneumology and Thoracic Surgery (Spanish acronym SEPAR, for Sociedad Española de Neumología y Cirugía Torácica)^{29, 30}. The equipment was calibrated weekly.

Exposure variables

Urine cotinine concentration. Each worker was asked to provide urine sample the morning after the spirometry measurements. The sample was provided, retrieved, and frozen on the same day. Urine cotinine concentration was measured using ELISA at a sensitivity of 1 ng/ml. The cut-off value typically used in the literature to distinguish smokers from nonsmokers is 10 ng/ml³¹. As a quality control, duplicate samples were obtained and analyzed. There was a strong correlation between the original and duplicate samples (Spearman's correlation=0.96; p-value=0.0005). Chronic exposure to SHS was measured as *the number*

of years exposed to SHS at workplace (number of years worked at their 3 most recent job
 positions and whether it involved SHS exposure).

Covariables

The questionnaire included items about the participant's health history (asthma diagnosis, smoking habits); occupational history (job function at the facility, secondary employment at another facility, number of hours per day and days per week worked); occupational exposure (number of hours per day and days per week exposed to SHS); and the type of facility (smoking, mixed, or non-smoking).

Statistical analysis

Data analysis was performed using the program STATA 12. The quantitative variables were assessed for normality using the Shapiro-Wilk test. Descriptive statistics were calculated, including median and interguartile ranges $(P_{25}-P_{75})$ for quantitative variables and relative frequency for qualitative variables. Quantitative exposure variables and covariables, such as number of hours per week of SHS exposure or age were dichotomized using the median as cutoff. Kruskal Wallis test and Wilcoxon test were used to assess difference of pulmonary parameters and exposure variables between the categories of the covariables. Finally, the association between pulmonary function parameters and exposure to SHS was analyzed using multiple linear regression models adjusted by covariates potentially associated with both, the outcome and the exposure considering a p-value of $< 0.10^{32}$, as well as variables commonly controlled for in the literature.

Results

The non-smoking workers evaluated in the study were 92. 17(18.5%) were excluded due to spirometry results failed to meet the criteria for acceptability and reproducibility. The final BMJ Open: first published as 10.1136/bmjopen-2017-017811 on 6 October 2017. Downloaded from http://bmjopen.bmj.com/ on April 19, 2024 by guest. Protected by copyright

Table 1. Characteristics of the study sample. Santiago, Chile 2010-2011.

U	owij Open							
sample was 75 workers. Median age wa	s 35 years	(P ₂₅ -P ₇₅ : 19-	-68 years), a	nd 61% of				
participants were male. 29.3% were for	mer smoker	s and the mo	edian of time	e they quit				
smoking was 8.5 years (RIC 2 to 15 years). They were homogeneously distributed at the								
different facility type. On average, partic	cipants had	worked at th	ne studied ve	nue for 12				
months. Independent of the facility type, t	he sample w	vas mainly co	mposed of wa	aiting staff,				
bartenders, and cashiers (70.7%). Workers	s in smoking	g facilities re	ported higher	number of				
weekly hours exposed to SHS compared to	o workers in	mixed and no	on-smoking f	acilities (p-				
value=0.0001) (Table 1).								
Table 1. Characteristics of the study sample	e Santiago (Chile 2010-20 1	11					
Table 1. Characteristics of the study sample	c. Santiago, v		atus restaurant/k	par/pub				
				· · · · · · · · · · · · · · · · · · ·				
	Total	-	Mixed	Non-smoking	p valu			
N° employees n (%)	Total	Smoking 27 (36.0)	Mixed 31 (41.3)	Non-smoking 17 (22.7)	p valu			
N° employees n (%) Sociodemographic characteristics		Smoking		0	p valu			
		Smoking		0	p valu 0.081*			
Sociodemographic characteristics	75 (100)	Smoking 27 (36.0)	31 (41.3)	17 (22.7)	-			
Sociodemographic characteristics Age, Median (P ₂₅ -P ₇₅)	75 (100)	Smoking 27 (36.0)	31 (41.3)	17 (22.7)	-			
Sociodemographic characteristics Age, Median (P ₂₅ -P ₇₅) Sex, n (%)	75 (100) 35.0 (19.0-62)	Smoking 27 (36.0) 40.0 (29.0-52.0)	31 (41.3) 35.0 (21.0-57.0)	17 (22.7) 31.0 (22.0-44.0)	0.081*			
Sociodemographic characteristics Age, Median (P ₂₅ -P ₇₅) Sex, n (%) Male	75 (100) 35.0 (19.0-62)	Smoking 27 (36.0) 40.0 (29.0-52.0)	31 (41.3) 35.0 (21.0-57.0)	17 (22.7) 31.0 (22.0-44.0)	0.081*			
Sociodemographic characteristics Age, Median (P ₂₅ -P ₇₅) Sex, n (%) Male Asthma, n (%)	75 (100) 35.0 (19.0-62) 46 (61.3)	Smoking 27 (36.0) 40.0 (29.0-52.0) 17 (63.0)	31 (41.3) 35.0 (21.0-57.0) 19 (61.3)	17 (22.7) 31.0 (22.0-44.0) 10 (59.0)	0.081*			
Sociodemographic characteristics Age, Median (P ₂₅ -P ₇₅) Sex, n (%) Male Asthma, n (%) Yes	75 (100) 35.0 (19.0-62) 46 (61.3) 8 (10.7)	Smoking 27 (36.0) 40.0 (29.0-52.0) 17 (63.0) 1 (3.7)	31 (41.3) 35.0 (21.0-57.0) 19 (61.3) 7 (22.6)	17 (22.7) 31.0 (22.0-44.0) 10 (59.0) 0	0.081*			
Sociodemographic characteristics Age, Median (P_{25} - P_{75}) Sex, n (%) Male Asthma, n (%) Yes No	75 (100) 35.0 (19.0-62) 46 (61.3) 8 (10.7)	Smoking 27 (36.0) 40.0 (29.0-52.0) 17 (63.0) 1 (3.7)	31 (41.3) 35.0 (21.0-57.0) 19 (61.3) 7 (22.6)	17 (22.7) 31.0 (22.0-44.0) 10 (59.0) 0	0.081*			
Sociodemographic characteristics Age, Median (P ₂₅ -P ₇₅) Sex, n (%) Male Asthma, n (%) Yes No Occupational exposure	75 (100) 35.0 (19.0-62) 46 (61.3) 8 (10.7)	Smoking 27 (36.0) 40.0 (29.0-52.0) 17 (63.0) 1 (3.7)	31 (41.3) 35.0 (21.0-57.0) 19 (61.3) 7 (22.6)	17 (22.7) 31.0 (22.0-44.0) 10 (59.0) 0	0.081*			
Sociodemographic characteristics Age, Median (P ₂₅ -P ₇₅) Sex, n (%) Male Asthma, n (%) Yes No Occupational exposure Job function at the facility, n (%)	75 (100) 35.0 (19.0-62) 46 (61.3) 8 (10.7) 67 (89.3)	Smoking 27 (36.0) 40.0 (29.0-52.0) 17 (63.0) 1 (3.7) 26 (96.3)	31 (41.3) 35.0 (21.0-57.0) 19 (61.3) 7 (22.6) 24 (77.4)	17 (22.7) 31.0 (22.0-44.0) 10 (59.0) 0 17 (100)	0.081*			
Sociodemographic characteristics Age, Median (P ₂₅ -P ₇₅) Sex, n (%) Male Asthma, n (%) Yes No Occupational exposure Job function at the facility, n (%) Owners/managers	75 (100) 35.0 (19.0-62) 46 (61.3) 8 (10.7) 67 (89.3) 8 (10.7)	Smoking 27 (36.0) 40.0 (29.0-52.0) 17 (63.0) 1 (3.7) 26 (96.3) 7 (25.9)	31 (41.3) 35.0 (21.0-57.0) 19 (61.3) 7 (22.6) 24 (77.4) 1 (3.2)	17 (22.7) 31.0 (22.0-44.0) 10 (59.0) 0 17 (100) 0	0.081* 0.963* 0.018*			
Sociodemographic characteristics Age, Median (P ₂₅ -P ₇₅) Sex, n (%) Male Asthma, n (%) Yes No Occupational exposure Job function at the facility, n (%) Owners/managers Wait staff/bartenders/cashiers	75 (100) 35.0 (19.0-62) 46 (61.3) 8 (10.7) 67 (89.3) 8 (10.7) 53 (70.7)	Smoking 27 (36.0) 40.0 (29.0-52.0) 17 (63.0) 1 (3.7) 26 (96.3) 7 (25.9) 13 (48.2)	31 (41.3) 35.0 (21.0-57.0) 19 (61.3) 7 (22.6) 24 (77.4) 1 (3.2) 27 (87.1)	17 (22.7) 31.0 (22.0-44.0) 10 (59.0) 0 17 (100) 0 13 (76.5)	0.081* 0.963* 0.018* 0.005*			
Sociodemographic characteristics Age, Median (P ₂₅ -P ₇₅) Sex, n (%) Male Asthma, n (%) Yes No Occupational exposure Job function at the facility, n (%) Owners/managers Wait staff/bartenders/cashiers Cooks	75 (100) 35.0 (19.0-62) 46 (61.3) 8 (10.7) 67 (89.3) 8 (10.7) 53 (70.7) 14 (18.7)	Smoking 27 (36.0) 40.0 (29.0-52.0) 17 (63.0) 1 (3.7) 26 (96.3) 7 (25.9) 13 (48.2) 7 (25.9)	31 (41.3) 35.0 (21.0-57.0) 19 (61.3) 7 (22.6) 24 (77.4) 1 (3.2) 27 (87.1) 3 (9.7)	17 (22.7) 31.0 (22.0-44.0) 10 (59.0) 0 17 (100) 0 13 (76.5) 4 (23.5)	0.081* 0.963* 0.018*			

Page 9 of 25

BMJ Open

As shown in Table 2 we compared the results for pulmonary function and exposure to SHS based on covariables. Males had greater pulmonary function values than females, except for FEV₁/FVC ratio, where no differences were observed. No differences in pulmonary function were observed between former smokers and never smokers groups. In terms of the occupational exposure variables, employees working in the kitchen had lower values for FVC, FEV_1 , and $FEF_{25/75}$ than the group of wait staff, bartenders, cashiers, and managers. Regarding the number of hours per week of SHS exposure and pulmonary function, exposure greater than 26 hours per week was associated with a 0.02% decrease in FEV_1/FVC and a 230 ml decrease in $FEF_{25/75}$ although these results were not statistically significant. Workers in smoking venues had FEF_{25/75} 400 ml lower and FEV₁/FVC ratios 0.03% lower than those of workers in non-smoking venues. In terms of urine cotinine concentration, although differences were observed between categories of job function and the hours per week exposed to SHS, these differences were strongly influenced by workplace's smoking policy. For example, in the case of wait staff/bartenders/cashiers working in venues where smoking was allowed, they had a median urinary cotinine concentration of 40.7 ng/ml. Employees working in mixed venues (with smoking and non-smoking areas) had a median of 13.5 ng/ml and those who working in smoke-free venues had a median of 2.5 ng/ml. In the same way, the information regarding urinary cotinine concentration in people working over 27 hours per week exposed to SHS in venues where smoking was allowed was 45.2 ng/ml, in those working in mixed venues the median was 13.6 ng/ml and in those working in smoke free venues the median was 2.0 ng/ml. The number of years exposed to SHS workplace varied according to sex, age and smoking status of employees.

Table 2. Pulmonary function and exposure to secondhand smoke at non-smoking workers. 1

2 Santiago, 2010-2011.

1

2 3 4

/ariables			Pulmonary fund	ction parameters		Urine cotinine concentration	Number of year exposed to SH
) 1	n	FVC	FEV ₁	FEV ₁ /FVC	FEF 25%/75%	(ng/ml)	workplace
2 3		ml (RIC)	ml (RIC)	% (RIC)	ml (RIC)	Med (P ₂₅ -P ₇₅)	Med $(P_{25}-P_{7})$
4 Jex 5							2-119 2
6Male 7	46	4.82 (4.23-5.42)	3.94 (3.41-4.38)	0.81 (0.76-0.84)	3.95 (3.00-4.66)	18.6 (6.2-39.5)	3.5 (1.0-11.3)
3Female	29	3.48 (3.16-3.90)	2.89 (2.65-3.34)	0.81 (0.79-0.89))	3.25 (2.56-3.83)	13.6 (7.3-41.1)	1.0 (0.16-4.0)
$9 D^{p \text{ value } \pm}$		0.0001	0.0001	0.116	0.014	0.944	1.0 (0.16-4.0) 0.01
2 1ge* 2							a C
$3 \le 35$ years	38	4.79 (3.93-5.36)	3.91 (3.37-4.38)	0.83 (0.79-0.88)	4.07 (3.27-4.59)	21.4 (5.1-40.7)	1.0 (0.25-5.0)
4 5>36 year	37	3.78 (3.21-4.42)	2.95 (2.61-3.62)	0.80 (0.78-0.83)	3.12 (2.53-3.95)	15.2 (9.7-38.1)	4.0 (1.0-11.7)
6 7p value ±		0.0002	0.0001	0.049	0.0009	0.787	0.02
moking status							0.02 0.02
Never smokers	53	4.23 (3.45-4.89)	3.49 (2.88-4.06)	0.81 (0.79-0.86)	3.69 (2.85-4.39)	21.7 (5.7-43.8)	1.0 (0.75-5.0)
1 2Former smokers	22	4.33 (3.58-5.32)	3.53 (2.99-4.26)	0.81 (0.76-0.85)	3.77 (3.0-4.59)	12.9 (9.4-36.8)	6.3 (0.83-11.7
3 4p value ±		0.767	0.684	0.452	0.907	0.629	0.04
$\frac{5}{5}$ b function at the facility							0.04 1.0 (0.8-4.1)
7 Owners/managers 8	8	4.84 (3.47-6.09)	3.94 (2.66-4.48)	0.77 (0.72-0.80)	3.22 (2.19-3.90)	41.0 (29.3-46.1)	1.0 (0.8-4.1)
Wait staff/bartenders/cashiers	53	4.42 (3.74-5.17)	3.56 (3.14-4.20)	0.82 (0.79-0.86)	3.94 (3.11-4.59)	13.2 (5.1-39.5)	3.0 (0.4-7.1)
) 1 Cooks	14	3.38 (2.96-4.24)	2.81 (2.56-3.62)	0.82 (0.79-0.86)	3.08 (2.53-3.80)	25.0 (9.7-36.9)	1.6 (0.8- 4.0)
² ² ³ ² ³ ² ³ ² ³ ² ³		0.03	0.04	0.04	0.03	0.08	1.6 (0.8- 4.0) 0.711
4 fours per week exposed to SHS*							
5 6≤26 hrs	39	4.05 (3.58-4.75)	3.44 (2.85-3.91)	0.82 (0.78-0.87)	3.81 (2.89-4.59)	11.3 (3.0-26.0)	2.0 (0.25-6.9
7 8 ^{>27} hrs	36	4.40 (3.45-5.40)	3.64 (2.89-4.32)	0.80 (0.77-0.84)	3.58 (2.78-4.38)	35.8 (11.6-48.1)	3.3 (0.9-7.04)
$\frac{9}{2}$ p value ±		0.279	0.457	0.173	0.603	0.0003	0.474
acility							3.3 (0.9-7.04) 0.474 2.6 (0.9-7.0) 1.5 (0-5.0)
2 3Smoking/mixed	58	4.24 (3.32-5.26)	3.49 (2.85-4.23)	0.81 (0.77-0.84)	3.58 (2.73-4.44)	21.8 (10.5-44.7)	2.6 (0.9-7.0)
4 5Non-smoking	17	4.24 (3.83-4.55)	3.49 (3.28-3.83)	0.84 (0.80-0.88)	3.98 (3.25-4.48)	4.1 (1.5-26.0)	1.5 (0-5.0)

- .
- 58
- 59
- 60

e 11 of 25							
value ±		0.825	0.845	0.06	0.176	0.0012	0.161
1	*Variable dicho	otomized in median value	• + Kruskal Wallis	test: +Wilcoxon	Test		
-	v unuble ulen		, · Kruskur Wums	<u>est, -</u> ((() () () () () ()) ()) ()) ())) ()) ())) ()) ())) () ()))) ())) ())) ()) ())))))) () 	1051		
2							
	~ •	• • • • •			• • • • • • •		
3	Consistent	with the literature	e, sex, age a	nd weight v	vere significantly	associated with	
4		formation management	ang (Tabla 2)	In tomas	of ich formation 4	ha arrang and	
4	pulmonary	function parameter	ers (Table 3)	. In terms	of job function, t	ne owners and	
5	managers h	ad FEV ₁ /FVC val	ues 60% low	er and FFFa	ara values 830 ml	lower than the	
J	managers		lues 0070 10w		5/75 values 050 mi	lower than the	
6	group of wa	ait staff, bartenders	s, and cashiers	s. The kitche	n workers had 700) ml lower FVC	
	0 1		,				
7	values, 640	ml lower FEV ₁ va	lues, and 772	ml lower FH	EF _{25/75} than the gro	up of wait staff,	
8	bartenders,	and cashiers. World	kers in smokii	ng facilities l	had 413 ml lower	$\text{FEF}_{25/75}$ and 3%	
	1						
9	lower FEV_1	/FVC than workers	s in non-smok	ing venues.			
10	Table 2 D:		of university	from ations and			
10	Table 3. Bi	variate association	of pulmonary	y function pa	arameters in non-s	mokers workers	
10 11				y function pa	arameters in non-s	mokers workers	
		variate association o covariables of inte		y function pa	arameters in non-s	mokers workers	
		o covariables of inte	erest.				
		o covariables of inte	erest.	FEV ₁ (ml)	FEV ₁ /FVC (ml)	FEF _{25/75} (ml)	
		$\frac{\text{covariables of inte}}{\frac{\text{FVC (ml)}}{\beta}}$	erest.	FEV_1 (ml)	FEV ₁ /FVC (ml) β	FEF _{25/75} (ml) β	
11		$\frac{\text{FVC (ml)}}{\beta}$ (CI95%)	erest.	FEV ₁ (ml)	FEV ₁ /FVC (ml)	FEF _{25/75} (ml)	. <u></u>
11	according to	$\frac{\text{FVC (ml)}}{\beta}$ (CI95%)	erest.	FEV_1 (ml)	FEV ₁ /FVC (ml) β	FEF _{25/75} (ml) β	
11 Socioder	according to	b covariables of interval $\frac{FVC (ml)}{\beta}$ (C195%) bles 1.26	erest. F (CIS 0.	FEV ₁ (ml) β 95%)	FEV ₁ /FVC (ml) β (C195%) -0.03	FEF _{25/75} (ml) β (CI95%) 0.61	,
11 Socioder Sex Male	according to	b covariables of inte FVC (ml) β (CI95%) bles	erest. F (CIS 0.	⁷ EV ₁ (ml) β 95%)	FEV ₁ /FVC (ml) β (Cl95%)	FEF _{25/75} (ml) β (CI95%)	
11 Socioder Sex	according to	b covariables of interval $\frac{FVC (ml)}{\beta}$ (CI95%) bles 1.26 (0.880 to 1.650)	erest. F (CIS 0. (0.601 t	FEV ₁ (ml) β 25%) 91 το 1.213)	FEV ₁ /FVC (ml) β (C195%) -0.03 (-0.064 to -0.0003)	FEF _{25/75} (ml) β (CI95%) 0.61 (0.110 to 1.103)	,
11 Socioder Sex Male	according to	b covariables of inte FVC (ml) β (CI95%) bles 1.26 (0.880 to 1.650) -0.03	erest. F (CI9 0. (0.601 t -0	FEV ₁ (ml) β 05%) 91 το 1.213) .03	FEV ₁ /FVC (ml) β (CI95%) -0.03 (-0.064 to -0.0003) -0.001	FEF _{25/75} (ml) β (CI95%) 0.61 (0.110 to 1.103) -0.04	
11 Socioder Sex Male Age	according to	b covariables of interval $\frac{FVC (ml)}{\beta}$ (CI95%) bles 1.26 (0.880 to 1.650)	erest. F (CI9 0. (0.601 t -0	FEV ₁ (ml) β 25%) 91 το 1.213)	FEV ₁ /FVC (ml) β (C195%) -0.03 (-0.064 to -0.0003)	FEF _{25/75} (ml) β (CI95%) 0.61 (0.110 to 1.103)	,
11 Socioder Sex Male	according to	b covariables of inter FVC (ml) β (CI95%) bles 1.26 (0.880 to 1.650) -0.03 (-0.05 to -0.02)	erest. F (CI9 0. (0.601 t -0 (-0.04 t	FEV ₁ (ml) β 95%) 91 o 1.213) .03 co -0.02)	FEV ₁ /FVC (ml) β (CI95%) -0.03 (-0.064 to -0.0003) -0.001 (-0.003 to -0.003)	FEF _{25/75} (ml) β (CI95%) 0.61 (0.110 to 1.103) -0.04 (-0.055 to -0.019)	
11 Socioder Sex Male Age	according to	b covariables of inte FVC (ml) β (CI95%) bles 1.26 (0.880 to 1.650) -0.03	erest. F (CI9 0. (0.601 t -0 (-0.04 t	FEV ₁ (ml) β 05%) 91 το 1.213) .03	FEV ₁ /FVC (ml) β (CI95%) -0.03 (-0.064 to -0.0003) -0.001	FEF _{25/75} (ml) β (CI95%) 0.61 (0.110 to 1.103) -0.04	,
11 Socioder Sex Male Age	according to	b covariables of inter FVC (ml) β (CI95%) bles 1.26 (0.880 to 1.650) -0.03 (-0.05 to -0.02)	erest. F (CIS 0. (0.601 t -0 (-0.04 t 0.	FEV ₁ (ml) β 95%) 91 o 1.213) .03 co -0.02)	FEV ₁ /FVC (ml) β (CI95%) -0.03 (-0.064 to -0.0003) -0.001 (-0.003 to -0.003)	FEF _{25/75} (ml) β (CI95%) 0.61 (0.110 to 1.103) -0.04 (-0.055 to -0.019)	
11 Socioder Sex Male Age	according to	$\frac{FVC (ml)}{\beta}$ (C195%) (C195%) (C195%) (0.880 to 1.650) -0.03 (-0.05 to -0.02) 0.04 (0.02 to 0.05)	erest. F (CIS 0. (0.601 t (-0.04 t 0. (0.01 t	FEV ₁ (ml) β 95%) 91 το 1.213) .03 το -0.02) 02 το 0.04)	FEV ₁ /FVC (ml) β (C195%) -0.03 (-0.064 to -0.0003) -0.001 (-0.003 to -0.003) -0.001 (-0.002 to -0.0001)	$\frac{\text{FEF}_{25/75} \text{ (ml)}}{\beta}$ (CI95%) 0.61 (0.110 to 1.103) -0.04 (-0.055 to -0.019) 0.01 (-0.004 to 0.034)	
11 Socioder Sex Male Age Weight	according to	$\frac{\text{FVC (ml)}}{\beta}$ (CI95%) bles 1.26 (0.880 to 1.650) -0.03 (-0.05 to -0.02) 0.04 (0.02 to 0.05) 0.08	erest. F (CIS 0. (0.601 t (-0.04 t 0. (0.01 t	EEV ₁ (ml) β 25%) 91 ο 1.213) .03 ο -0.02) 02	FEV ₁ /FVC (ml) β (C195%) -0.03 (-0.064 to -0.0003) -0.001 (-0.003 to -0.003) -0.001	FEF _{25/75} (ml) β (C195%) 0.61 (0.110 to 1.103) -0.04 (-0.055 to -0.019) 0.01	
11 Socioder Sex Male Age Weight	according to	$\frac{FVC (ml)}{\beta}$ (C195%) (C195%) (C195%) (0.880 to 1.650) -0.03 (-0.05 to -0.02) 0.04 (0.02 to 0.05)	Prest. F (CIS 0. (0.601 t -0 (-0.04 t 0. (0.01 t 0.	FEV ₁ (ml) β 95%) 91 το 1.213) .03 το -0.02) 02 το 0.04)	FEV ₁ /FVC (ml) β (C195%) -0.03 (-0.064 to -0.0003) -0.001 (-0.003 to -0.003) -0.001 (-0.002 to -0.0001)	$\frac{\text{FEF}_{25/75} \text{ (ml)}}{\beta}$ (CI95%) 0.61 (0.110 to 1.103) -0.04 (-0.055 to -0.019) 0.01 (-0.004 to 0.034)	
11 Socioder Sex Male Age Weight Size Asthma	according to	$\frac{FVC (ml)}{\beta}$ (C195%) oles 1.26 (0.880 to 1.650) -0.03 (-0.05 to -0.02) 0.04 (0.02 to 0.05) 0.08 (0.07 to 0.10)	Prest. F (CIS 0. (0.601 t -0 (-0.04 t 0. (0.01 t 0. (0.050 t	EV ₁ (ml) β 95%) 91 o 1.213) .03 o -0.02) 02 o 0.04) 06 o 0.074)	$\frac{FEV_{1}/FVC (ml)}{\beta}$ (C195%) -0.03 (-0.064 to -0.0003) -0.001 (-0.003 to -0.003) -0.001 (-0.002 to -0.0001) -0.001 (-0.002 to 0.001) (-0.002 to 0.001)	$\frac{\text{FEF}_{25/75} \text{ (ml)}}{\beta}$ (C195%) 0.61 (0.110 to 1.103) -0.04 (-0.055 to -0.019) 0.01 (-0.004 to 0.034) 0.05 (0.029 to 0.076)	
11 Socioder Sex Male Age Weight Size	according to	$\begin{array}{c} FVC (ml) \\ \beta \\ (C195\%) \\ \textbf{oles} \\ \hline 1.26 \\ (0.880 \text{ to } 1.650) \\ -0.03 \\ (-0.05 \text{ to } -0.02) \\ 0.04 \\ (0.02 \text{ to } 0.05) \\ 0.08 \\ (0.07 \text{ to } 0.10) \\ 0.04 \end{array}$	Prest. F (CIS 0. (0.601 t -0 (-0.04 t 0. (0.01 t 0. (0.050 t -0	$\frac{FEV_1 (ml)}{\beta}$ 91 o 1.213) .03 o -0.02) 02 o 0.04) 06 o 0.074) .17	$\frac{FEV_{1}/FVC (ml)}{\beta}$ (C195%) -0.03 (-0.064 to -0.0003) -0.001 (-0.003 to -0.003) -0.001 (-0.002 to -0.0001) -0.001 (-0.002 to 0.0001) -0.001 (-0.002 to 0.001) -0.05	$\frac{\text{FEF}_{25/75} \text{ (ml)}}{\beta}$ (C195%) 0.61 (0.110 to 1.103) -0.04 (-0.055 to -0.019) 0.01 (-0.004 to 0.034) 0.05 (0.029 to 0.076) -0.67	
11 Socioden Sex Male Age Weight Size Asthma Yes	according to	$\begin{array}{c} \hline \textbf{FVC (ml)} \\ \hline \beta \\ (C195\%) \\ \textbf{bles} \\ \hline 1.26 \\ (0.880 \text{ to } 1.650) \\ -0.03 \\ (-0.05 \text{ to } -0.02) \\ \hline 0.04 \\ (0.02 \text{ to } 0.05) \\ \hline 0.08 \\ (0.07 \text{ to } 0.10) \\ \hline 0.04 \\ (-0.731 \text{ to } 0.802) \end{array}$	Prest. F (CIS 0. (0.601 t -0 (-0.04 t 0. (0.01 t 0. (0.050 t -0	EV ₁ (ml) β 95%) 91 o 1.213) .03 o -0.02) 02 o 0.04) 06 o 0.074)	$\frac{FEV_{1}/FVC (ml)}{\beta}$ (C195%) -0.03 (-0.064 to -0.0003) -0.001 (-0.003 to -0.003) -0.001 (-0.002 to -0.0001) -0.001 (-0.002 to 0.001) (-0.002 to 0.001)	$\frac{\text{FEF}_{25/75} \text{ (ml)}}{\beta}$ (C195%) 0.61 (0.110 to 1.103) -0.04 (-0.055 to -0.019) 0.01 (-0.004 to 0.034) 0.05 (0.029 to 0.076)	<u>,</u>
11 Socioder Sex Male Age Weight Size Asthma Yes	according to	$\begin{array}{c} \hline \textbf{FVC (ml)} \\ \hline \beta \\ (C195\%) \\ \textbf{bles} \\ \hline 1.26 \\ (0.880 \text{ to } 1.650) \\ -0.03 \\ (-0.05 \text{ to } -0.02) \\ \hline 0.04 \\ (0.02 \text{ to } 0.05) \\ \hline 0.08 \\ (0.07 \text{ to } 0.10) \\ \hline 0.04 \\ (-0.731 \text{ to } 0.802) \end{array}$	Prest. F (CIS 0. (0.601 t -0 (-0.04 t 0. (0.01 t 0. (0.050 t -0	$\frac{FEV_1 (ml)}{\beta}$ 91 o 1.213) .03 o -0.02) 02 o 0.04) 06 o 0.074) .17	$\frac{FEV_{1}/FVC (ml)}{\beta}$ (C195%) -0.03 (-0.064 to -0.0003) -0.001 (-0.003 to -0.003) -0.001 (-0.002 to -0.0001) -0.001 (-0.002 to 0.0001) -0.001 (-0.002 to 0.001) -0.05	$\frac{\text{FEF}_{25/75} \text{ (ml)}}{\beta}$ (C195%) 0.61 (0.110 to 1.103) -0.04 (-0.055 to -0.019) 0.01 (-0.004 to 0.034) 0.05 (0.029 to 0.076) -0.67	
11 Socioder Sex Male Age Weight Size Asthma Yes	according to	$\begin{array}{c} \hline \textbf{FVC (ml)} \\ \hline \beta \\ (C195\%) \\ \textbf{bles} \\ \hline 1.26 \\ (0.880 \text{ to } 1.650) \\ -0.03 \\ (-0.05 \text{ to } -0.02) \\ \hline 0.04 \\ (0.02 \text{ to } 0.05) \\ \hline 0.08 \\ (0.07 \text{ to } 0.10) \\ \hline 0.04 \\ (-0.731 \text{ to } 0.802) \end{array}$	Prest. F (CIS 0. (0.601 t -0 (-0.04 t 0. (0.01 t 0. (0.050 t -0	$\frac{FEV_1 (ml)}{\beta}$ 91 o 1.213) .03 o -0.02) 02 o 0.04) 06 o 0.074) .17	$\frac{FEV_{1}/FVC (ml)}{\beta}$ (C195%) -0.03 (-0.064 to -0.0003) -0.001 (-0.003 to -0.003) -0.001 (-0.002 to -0.0001) -0.001 (-0.002 to 0.0001) -0.001 (-0.002 to 0.001) -0.05	$\frac{\text{FEF}_{25/75} \text{ (ml)}}{\beta}$ (C195%) 0.61 (0.110 to 1.103) -0.04 (-0.055 to -0.019) 0.01 (-0.004 to 0.034) 0.05 (0.029 to 0.076) -0.67	

58 59 60

BMJ Open: first published as 10.1136/bmjopen-2017-017811 on 6 October 2017. Downloaded from http://bmjopen.bmj.com/ on April 19, 2024 by guest. Protected by copyright

Wait staff/bartenders/cash	iers <i>Ref.</i>	Ref.	Ref.	Ref.
Owners/managers	0.37	0.003	-0.06	-0.83
	(-0.370 to 1.110)	(-0.570 to 0.570)	(-0.113 to -0.021)	(-1.613 to -0.047
Cooks	-0.70	-0.64	-0.02	-0.77
	(-1.290 to -0.120)	(-1.090 to -0.190)	(-0.061 to 0.022)	(-1.391 to -0.151
Iours per week exposed to S	SHS			
	0.01	0.01	-0.0004	0.002
	(0.002 to 0.020)	(-0.0005 to 0.014)	(-0.001 to 0.0002)	(-0.008 to 0.011)
acility				
Non-smoking	Ref.	Ref.	Ref.	Ref.
Smoking/mixed	0.10	-0.05	-0.03	-0.41
	(-0.460 to 0.672)	(-0.486 to 0.381)	(-0.071 to 0.003)	(-1.003 to 0.177

2 Association between pulmonary function and SHS exposure

The crude model revealed that the association between pulmonary function and urine cotinine concentration was not statistically significant (Table 4). The multivariate analysis was based on a parsimonious model that included the covariate "job function", as this variable was related to pulmonary function and urine cotinine concentration with a p-value<0.10, as well as the variables sex, age, weight, height, and asthma status, all of which are recognized as variables that affect pulmonary function according to SEPAR^{29, 32}. The adjusted model did not demonstrate a significant association between urine cotinine concentration and decreased pulmonary function. Conversely, the number of years of SHS exposure in workplace showed an inverse and significant association with FEV_1 . Each year of SHS exposure was associated with a 200 ml decrease in FEV₁ (95% CI -0.042 to -0.001). The other pulmonary function variables were also inversely associated with years of SHS exposure in workplace, although the association in these cases did not reach significance. The adjusted model showed an inverse and in some cases statistically significant

BMJ Open

Table 4. Crude and adjusted association between pulmonary function parameters and

SHS exposure of non-smoking workers of bars and restaurants.

			вмј Оре					
	on between the rs, specifically in		-			-	nary function	
	Crude and adjus osure of non-smo					on pai	ameters and	
	FVC (ml)		FEV_1 (ml)		FEV ₁ /FVC (n	nl)	FEF25/75 (ml)	
	β (CI95%)	R ²	β (CI95%)	R ²	β (CI95%)	R ²	β (CI95%)	R ²
Urine cotinine		6						
Crude model	0.002	0.002	0.002	0.003	0.0002	0.002	0.002	0.002
	(-0.010 to 0.010)		(-0.010 to 0.010)		(-0.001 to 0.001)		(-0.010 to 0.010)	
Adjusted model	-0.0002	0.781	0.001	0.795	0.0004	0.33	0.005	0.672
	(-0.007 to 0.006)*		(-0.003 to 0.006)*		(-0.0003 to 0.001)+		(-0.006 to 0.015)+	
Number of	years exposed to SHS	at work						
Crude model	-0.025	0.046	-0.022	0.061	-0.0008	0.013	-0.022	0.032
	(-0.051 to 0.002)		(-0.042 to -0.001)		(-0.002 to 0.0008)		(-0,050 to 0,006)	
Adjusted model	-0.013	0.79	-0.01	0.802	0.0006	0.324	-0.006	0.964
	(-0.030 to 0.0025)*		(-0.022 to 0.002)*		(-0.001 to 0.002)+		(-0,010 to -0,0004)+	

1 Discussion

This study is the first in Chile to evaluate occupational SHS exposure and its association with specific pulmonary function parameters. We did not find an inverse association between pulmonary function parameters and urine cotinine concentration, but when we considered number of years exposed to SHS in workplace, we found an inverse association with FVC (ml), FEV₁ (ml), FEV₁/FVC (ml) and FEF _{25/75} being significant only for the last parameter. Similar findings were described by other researchers who reported a reduction in FVC and $\text{FEF}_{25/75}^{20, 33}$, in FVC¹⁵, in FVC and FEV1^{16} in subjects exposed to environmental tobacco smoke. In terms of job function, kitchen workers showed lower pulmonary function values than the group of wait staff, bartenders, and cashiers as compared to the owners and managers. One possible explanation for these findings is that the SHS exposure had an additive effect with exposure to other pollutants emitted in the kitchen. In the literature has been reported that workers in kitchens with gas stoves show lower pulmonary function parameters than those in kitchens with electric stoves, due to greater exposure to toxic substances in the air after cooking with gas³⁴. In our study, it was not possible to analyze differences according this variable because 100% of the establishments used gas stoves.

As noted above, we did not find a significant association between pulmonary function parameters and urine cotinine concentration. A possible explanation for these results is that, urine cotinine levels reflect recent exposure to tobacco smoke^{21, 22, 31} while chronic exposure to SHS is likely implicated in a decline in pulmonary function parameters. In fact, in Table 4 we can see that the proportion of the variance (R^2) explained by *number of years of SHS exposure in workplace* is greater than that explained by the current *urine cotinine*

BMJ Open

concentration, suggesting that this variable (*number of years of SHS exposure*) may be more appropriate when we are studying chronic effects. Other studies that have addressed this topic have produced varying results^{15-17, 20-22, 31, 35} reported a significant inverse association between SHS exposure (evaluated through self-report) and FVC and FEV₁. As in our study, Chen et al. did not find a significant association when serum cotinine was assess as exposure variable, but did when exposure to SHS was measured through selfreport¹⁶.

Our results are not as strong as those described in other studies^{12-14, 20, 33}. It should be noted that our sample included mainly young workers being reasonable to infer that the sample not accumulated sufficient years of SHS exposure to register significant changes in pulmonary function. Also the median time worked at the location was only about 1 year. About 25% of the sample had worked at the given facility for less than 3 months, and 75% of the sample had worked at the location for fewer than 2 years. This condition of high turnover rate, along with the relative youth of the workers contributes to assume that the sample not accumulated enough years of SHS exposure to register significant changes in pulmonary function. A second limitation was that although all participants were non-smokers, those who worked in non-smoking venues reported be exposed to SHS at least 4 hours a week. Also in this group the median urine concentration was 4.1 ng/ml. The lack of a true control group could have lead to underestimating the effect of SHS exposure. Another potential limitation was the timing of the spirometry measurements. The literature reports that pulmonary function varies throughout the day according to circadian rhythm, decreasing from a high point in the early morning until about noon and then rising again to peak between about 4 and 5 in the afternoon. These daily fluctuations may have

Page 16 of 25 BMJ Open: first published as 10.1136/bmjopen-2017-017811 on 6 October 2017. Downloaded from http://bmjopen.bmj.com/ on April 19, 2024 by guest. Protected by copyright

BMJ Open

affected the results, as the lung function measurements were performed at various times of
day, according to the availability and shifts of the workers and establishments. Finally, our
small sample size along with the weak correlation between exposure to SHS and pulmonary
function prevent us to have enough power to demonstrate a strongest association as shown
in other studies.

Notwithstanding the above, our study shows that exposure to SHS among non-smoking employees working in venues where smoking is allowed appear to be substantially higher than those found in employees working in venues where smoking is not allow. The median urine cotinine in non-smoking employees working in a venue were smoking is allowed was 38.1 ng/ml, in a mixed venue was 12.5 ng/ml and where smoking was not allow was 4.1 ng/ml. Given that SHS is a proven carcinogen in humans to which non-smoking workers of this type of venues are exposed involuntarily, a total smoking ban would provide a major protection to employees working in such venues.

14 Conclusion

The years of exposure to SHS in workplace as proxy of chronic exposure were inverse and significantly associated with the FEF_{25/75}, and inverse but not significant with FVC and FEV₁. These findings suggest that cumulative exposure to SHS at work may contribute to deterioration of pulmonary function in non-smoking employees.

19 Acknowledgments

The authors would like to thank to employees, managers and venue owners who agreed to
participate in this study. Also to the Department of Research of the Universidad de Los

22 Andes-Chile for the support given to translate this article.

1 Data Sharing

2 No additional data available.

Competing interest

4 The authors have no conflict of interest to declare.

5 Funding

This study was supported by National Fund for Research and Development in Health
FONIS, CONICYT – MINSAL, Research Grant # SA09I062 and by International Training
and Research in Environmental and Occupational Health (ITREOH), Fogarty International
Center, NIH Research Grant #D43TW005746-02.

10 References

- Aceituno P, Iglesias V, Erazo M, Droppelmann A, Orellana C, Navas-Acién A. The
 work environment as a source of exposure to secondhand smoke: a study in workers of
 bars and restaurants of Santiago, Chile. *Rev Med Chile* 2010;138:1517-1523.
- 14 2. Alwan A. World Health Organization. WHO Report on the Global Tobacco Epidemic.
- 15 Implementing smoke-free environments, 2009. [Cited 2016 Jun 24]. Available from:
- 16 <u>http://who.int/tobacco/mpower/2009/gtcr_download/en/index.html</u>
- 17 3. Bello S, Michalland S, Soto M, Contreras C, Salinas J. Effects in passive smokers of
- 18 environmental tobacco smoke exposure. *Rev Chil Enf Respir* 2005;21:179-192.
- Chan-Yeung M, Dimich-Ward H. Respiratory health effects of exposure to
 environmental tobacco smoke. *Respirology* 2003;8(2):131-139.

BMJ Open: first published as 10.1136/bmjopen-2017-017811 on 6 October 2017. Downloaded from http://bmjopen.bmj.com/ on April 19, 2024 by guest. Protected by copyright

	1	5.	Collishaw NE, Kirkbride J, Wigle D. Tobacco smoke in the workplace: an occupational
	2		health hazard. Can Med Assoc J 1984;131(10):1191-1204.
	3	6.	EPA. Proposed identification of environmental tobacco smoke as a Toxic Air
	4		Contaminant. Tobacco Control. Surveys and Program Evaluations from Outside UCSF
	5		Paper CALEPA, 2005. [cited 2017 July 18]; Available from:
	6		https://oehha.ca.gov/media/downloads/air/report/app32005.pdf
	7	7.	Department of Health and Human Services USA. The consequences of smoking on
	8		health. 50 years of progress. Report of the US Department of Health and Human
	9		Services USA. Executive Summary, 2014.
1	.0	8.	OMS-OPS. Report on tobacco control in the Region of the Americas. 10 years of the
1	.1		Framework Convention of the World Health Organization for tobacco control.
1	.2		Washington D.C, 2016.
1	.3	9.	Allwright S, Paul G, Greiner B, Mullally BJ, Pursell L, Kelly A, et al. Legislation for
1	.4		smoke-free workplaces and health of bar workers in Ireland: before and after study.
1	.5		<i>BMJ</i> 2006;332(7534):151.
1	.6	10	. Coultas D. Health effects of passive smoking. Passive smoking and risk of adult asthma
1	.7		and COPD: an update. <i>Thorax</i> 1998;53(5):381-387.
1	.8	11	. De Vito E, Rojas R. Environmental tobacco smoke. Medicina (B. Aires)
1	.9		2005;65(6):545-549.
2	20	12	. Jaakkola M, Jaakkola J, Becklake M, Ernst P. Passive smoking and evolution of lung
2	21		function in young adults. An 8-year longitudinal study. J Clin Epidemiol
2	22		1995;48(3):317-327.

Page 19 of 25

BMJ Open

1	13. Jayet PY, Schindler C, Schwartz J, Kunzli N, Zellweger P, Ackermann-Liebrich U,
2	Leuenberger P. Passive smoking exposure among adults and the dynamics of
3	respiratory symptoms in a prospective multicenter cohort study. Scand J Work Environ
4	Health 2005;31(6):465-473.
5	14. Rizzi M, Sergi M, Andreoli A, Pecis M, Bruschi C, Fanfulla F. Environmental tobacco
6	smoke may induce early lung damage in healthy male adolescents. Chest
7	2004;125(4):1387-1393.
8	15. Alipour S, Deschamps F, Lesage F. Effects of Environmental Tobacco Smoke on
9	Respiratory Symptoms and Pulmonary Function. Inhal Toxicol 2005;18(8):569-573.
10	16. Chen R, Tunstall-Pedoe H, Tavendale R. Environmental tobacco smoke and lung
11	function in employees who never smoked: the Scottish MONICA study. Occup Environ
12	Med 2001;58(9):563-568.
13	17. Fidan F, Cimrin AH, Ergor G, Sevinc C. Airway disease risk from environmental
14	tobacco smoke among coffeehouse workers in Turkey. <i>Tob Control</i> 2004;13(2):161-6.
15	18. Janson C, Chinn S, Jarvis D, Zock JP, Torén K, Burney P. Effects of passive smoking
16	on respiratory symptoms, bronchial responsiveness, lung function, and total serum IgE
17	in the European Community Respiratory Health survey: a cross sectional study. Lancet
18	2001;358(2):103-109.
19	19. Eisner Mark D. Environmental tobacco smoke exposure and pulmonary function among
20	adults in NHANES III: impact on the general population and adults with current
21	asthma. Environ Health Perspect 2002;110(8):765-70.
22	20. Kunzli N, Schwartz J, Stutz EZ, Ackermann-Liebrich U, Leuenberger P. Association of
23	environmental tobacco smoke at work and forced expiratory lung function among never
	19

1	smoking asthmatics and non-asthmatics. The SAPALDIA-Team. Swiss Study on Air
2	Pollution and Lung Disease in Adults. Soz Praventivmed 2000;45(5):208-17.
3	21. Benowitz NL. Biomarkers of environmental tobacco smoke exposure. Environ Health
4	Perspect 1999;107(2):349-55.
5	22. Tutka P, Mosiewicz J, Wielosz M. Pharmacokinetics and metabolism of nicotine.
6	Pharmacol Rep 2005;57(2):143-53.
7	23. Centers for Disease Control and Prevention. National Report of Human Exposure to
8	Environmental Chemicals, 2017. [Cited 2017 March 15]. Available from:
9	https://www.cdc.gov/exposurereport/
10	24. Al-Delaimy WK, Crane J, Woodward A. Questionnaire and hair measurement of
11	exposure to tobacco smoke. J Expo Anal Environ Epidemiol 2000;10:378-384.
12	25. Al-Delaimy WK. Hair as a biomarker for exposure to tobacco smoke. Tob Control
13	2002;11:176-182.
14	26. Iglesias V, Erazo M, Droppelmann A, Steenland K, Aceituno P, Orellana C, Acuña M,
15	Peruga A, Breysse PN, Navas-Acien A. Occupational secondhand smoke is the main
16	determinant of hair nicotine concentrations in bar and restaurant workers. Environ Res
17	2014;132:206–211.
18	27. Salud OMS. "Convenio Marco de la OMS para el control del tabaco", 2013. [Cited
19	2016 Jun 24]. Available from: http://www.who.int/fctc/text_download/es/.
20	28. Muñoz C, Droppelmann A, Erazo M, Aceituno P, Orellana C, Parro J, Mesias S,
21	Marchetti N, Navas-Acien A, Iglesias V. Occupational exposure to polycyclic aromatic
22	hydrocarbons: A cross-sectional study in bars and restaurants in Santiago, Chile. Am J
23	Ind Med 2016; Version of record online: 28 Jun 2016.
	20

BMJ Open

ω
ž
2
2
$\underline{\circ}$
õ
Ψ
÷
S
¥
σ
č
σ
S
÷
ō
ŏ
01
8
1
-
<u></u>
8
Š
9
3
Ľ.
ŏ
Ō
÷
^k
č
ĭ
7
Ļ
Ξ
7
õ
<u> </u>
ublished as 10.1136/bmjopen-2017-017811 on 6
0
Š
6
ž
1 6 Octob
<u>Ω</u>
Ö
σ
Φ
2
2
7
ŏ
Ň
ber 2017. Down
) ownlc
) ownloa
ownload
ownloade
ownloaded
BMJ Open: first published as 10.1136/bmjopen-2017-017811 on 6 October 2017. Downloaded fr
ownloaded fro
ownloaded from
ownloaded from I
ownloaded from ht
ownloaded from http
rom http
rom http
rom http
rom http
ownloaded from http://bmjo
rom http
rom http://bmjopen.bmj.com/ on Ap
rom http
rom http://bmjopen.bmj.com/ on Ap

1	29. Burgos F, Casan P, Del Campo F, Gáldiz J, Giner J, González-Mangado N, Ortega F,
2	Puente L, García F, Calle M.
3	SEPAR Regulation: Forced Spirometry, 2013. [Cited 2016 Jun 24]. Available from:
4	http://www.ics.gencat.cat/3clics/guies/184/img/guiasepar20131.pdf
5	30. Gutiérrez M, Beroíza T, Barzone G, Caviedes I, Céspedes I, Céspedes J, Gutiérrez NM,
6	Moreno R, Oyarzún M, Palacios S, Schonffeldt P. Spirometry: Procedures Manual.
7	Chilean Society of Respiratory Diseases, 2006. Rev Chil Enf Respir 2007;23:31-42.
8	31. Vine M, Hulka B, Margolin B, Truong Y, Hu PC, Schramm M, Griffith J, McCann M,
9	Everson R. Cotinine Concentrations in Semen, Urine, and Blood of Smokers and
10	Nonsmokers. Am J Public Health 1993;83(9):1335-1338.
11	32. Tong S, Lu Y. Identification of confounders in the assessment of the relationship
12	between lead exposure and child development. Ann Epidemiol 2001;11(1): 38-45.
13	33. Fahim AE, El-Prince M. Passive smoking, pulmonary function and bronchial hyper-
14	responsiveness among indoor sanitary workers. Industrial health 2012;59: 516-520.
15	34. Wong TW, Wong AH, Lee FS, Qiu H. Respiratory health and lung function in Chinese
16	restaurant kitchen workers. Occup Environ Med 2011;68(10):746-752.
17	35. Skogstad M, Kjaerheim K, Fladseth G, GjØlstad M, Daae HL, Olsen R, Molander P,
18	Ellingsen DG. Cross shift changes in lung function among bar and restaurant workers
19	before and after implementation of a smoking ban. Occup Environ Med 2006;63:482-
20	487.
21	Contributorship statement

Parro Javiera. Substantial contributions to the conception and design of the work on pulmonary function parameters; acquisition, analysis and interpretation of data, drafting the work, and final approval of the version to be published; Aceituno Paulina. Substantial contributions to the conception and design of the work, revising it critically for important intellectual content, final approval of the version to be published. Droppelman Andrea. Substantial contributions to the conception, design of the work and interpretation of exposure data, final approval of the version to be published. Mesías Sthepanie. Substantial contributions to the acquisition and analysis of exposure data, final approval of the version to be published. Muñoz Claudio. Substantial contributions to the acquisition, analysis and interpretation of data, final approval of the version to be published. Marchetti Nella. Substantial contributions to the conception of the work and interpretation of data, final approval of the version to be published. Iglesias Verónica. Substantial contributions to the conception and design of the work, analysis and interpretation of data for the work: drafting the work, final approval of the version to be published, agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

BMJ Open

STROBE Statement-checklist of items that should be included in reports of observational studies

	Item No	Recommendation
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract page 1 line $1-2$
		(b) Provide in the abstract an informative and balanced summary of what was done
		and what was found
		page 2 line 1-22
Introduction		
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported
č		page 3-5
Objectives	3	State specific objectives, including any prespecified hypotheses
		page 5 line 4
Methods		
Study design	4	Present key elements of study design early in the paper page 5 line 8
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment,
		exposure, follow-up, and data collection page 5 line 13-23
Participants	6	(a) Cohort study—Give the eligibility criteria, and the sources and methods of
		selection of participants. Describe methods of follow-up
		Case-control study—Give the eligibility criteria, and the sources and methods of
		case ascertainment and control selection. Give the rationale for the choice of cases
		and controls
		<i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of
		selection of participants page 5 line 13-23
		(b) Cohort study—For matched studies, give matching criteria and number of
		exposed and unexposed
		Case-control study—For matched studies, give matching criteria and the number of
		controls per case
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect
		modifiers. Give diagnostic criteria, if applicable page 6 line 4-23, page 7 line 1-8
Data sources/	8*	For each variable of interest, give sources of data and details of methods of
measurement		assessment (measurement). Describe comparability of assessment methods if there is
		more than one group page 6 line 4-23, page 7 line 1-8
Bias	9	Describe any efforts to address potential sources of bias
Study size	10	Explain how the study size was arrived at NO
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable,
		describe which groupings were chosen and why page 7 line 19-22, page 8 line 1-8.
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding
		page 7 line 10-20
		(b) Describe any methods used to examine subgroups and interactions page 7 line
		10-20
		(c) Explain how missing data were addressed not apply
		(d) Cohort study—If applicable, explain how loss to follow-up was addressed
		<i>Case-control study</i> —If applicable, explain how nots to follow-up was addressed
		addressed
		<i>Cross-sectional study</i> —If applicable, describe analytical methods taking account of
		cross-sectional stady—in applicable, describe analytical methods taking account of

BMJ Open: first published as 10.1136/bmjopen-2017-017811 on 6 October 2017. Downloaded from http://bmjopen.bmj.com/ on April 19, 2024 by guest. Protected by copyright



BMJ Open

Results		
Participants	13*	(a) Report numbers of individuals at each stage of study-eg numbers potentially eligible,
		examined for eligibility, confirmed eligible, included in the study, completing follow-up, and
		analysed page 8 line 1-8
		(b) Give reasons for non-participation at each stage page 8 line 1-8
		(c) Consider use of a flow diagram NO
Descriptive	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information
data		on exposures and potential confounders page 8 table 1
		(b) Indicate number of participants with missing data for each variable of interest not apply
		(c) Cohort study—Summarise follow-up time (eg, average and total amount)
Outcome data	15*	Cohort study—Report numbers of outcome events or summary measures over time
		Case-control study-Report numbers in each exposure category, or summary measures of
		exposure
		Cross-sectional study—Report numbers of outcome events or summary measures NO
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their
		precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and
		why they were included page 13 Table 4
		(b) Report category boundaries when continuous variables were categorized page 10 Table 2
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful
		time period NO
Other analyses	17	Report other analyses done-eg analyses of subgroups and interactions, and sensitivity
		analyses NO
Discussion		
Key results	18	Summarise key results with reference to study objectives page 14 line 2-17
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision.
		Discuss both direction and magnitude of any potential bias page 15 line 8-23 page 16 line 1-5
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity
		of analyses, results from similar studies, and other relevant evidence page 16 line 15-18
Generalisability	21	Discuss the generalisability (external validity) of the study results NO
Other informati	on	
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable,
		for the original study on which the present article is based page 17 line 2

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at www.strobe-statement.org.